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1.  ABSTRACT 
 
In pancreatic acinar atrophy (PAA) a selective destruction of digestive enzyme-producing 
acinar cells leads to maldigestion signs typical of exocrine pancreatic insufficiency (EPI). 
Etiopathogenesis of PAA has remained obscure. A genetic predisposition to PAA has been 
reported in German shepherd dogs and rough-coated Collies. This study was set out to 
examine the etiopathogenesis of PAA; to find a method for the early diagnosis of exocrine 
pancreatic dysfunction, and thus, to study morphological and immunological findings when 
the disease is in progress. Also, an assessment was made for the long-term prognosis of 
enzyme replacement therapy in dogs with clinical disease.  
 
Abnormally low serum trypsin-like immunoreactivity, cTLI, values (< 2.5 µg/L; normal range 
> 5.0 –35.0 µg/L) associated with typical maldigestion signs of EPI, are considered diagnostic 
for clinical EPI and found in dogs with end-stage PAA. Study I showed that serum cTLI 
measurement is also valuable for diagnosing subclinical exocrine pancreatic dysfunction. 
Repeatedly low serum cTLI values (< 5.0 µg/L) were found in 12 German shepherd dogs and 
rough-coated Collies with no clinical signs of EPI. Laparotomy verified partial pancreatic 
acinar atrophy (partial PAA) in all the dogs. Pancreatic findings were comparable to those of 
end-stage PAA, but less severe. Based on this result, it was concluded that repeatedly low 
serum cTLI values (< 5.0 µg/L) in clinically normal dogs indicate subclinical EPI, and 
suggest partial PAA. 
 
An ability to diagnose PAA before the development of total atrophy offered an opportunity to 
study histological and ultrastructural findings whilst tissue destruction was still in progress, in 
the subclinical phase of the atrophy process (Study II). The main histological finding in the 
subclinical phase was marked lymphocytic infiltration into the exocrine pancreas. This 
differed distinctly from the usually mild inflammation detected during end-stage PAA. The 
inflammatory reaction was most extensive in the border zone areas of normal and affected 
parenchyma, and the lymphocytes had infiltrated into apparently normal acinar tissue. In areas 
of more advanced tissue destruction, the findings were similar to those in end-stage PAA. The 
ultrastructural findings were in accordance with those of the histological study. Based on 
these findings, the progression of acinar atrophy was divided into lymphocytic pancreatitis 
with active destruction of acinar structures and the end-stage PAA. Thus, the term “atrophic 
lymphocytic pancreatitis” is preferred to describe the pathological findings.  
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The role of cellular immunity in the pathogenesis of acinar atrophy was studied by 
immunophenotyping the lymphocytes infiltrating the tissue (Studies II and III). In the 
subclinical phase, the majority of the lymphocytes in the exocrine pancreas were T-cells with 
an almost equal number of CD4+ T-helper cells and CD8+ cytotoxic T-lymphocytes. The 
CD8+ cells had infiltrated both the affected and the normal parenchyma. They were 
considered to be the predominant cells in the areas of gradual destruction of the acinar tissue. 
Screening the humoral immune status included an assessment of serum autoantibodies (Study 
III). Serum autoantibodies reacting with pancreatic acinar cells were found in some dogs with 
subclinical and clinical phase of PAA. Although pancreatic-antibodies were not found in the 
healthy control dogs, the intensity of the positive reaction was so weak that these antibodies 
cannot be considered pathognomonic or diagnostic for the disease. 
 
This etiopathogenetic study suggests that pancreatic acinar atrophy in German shepherd dogs 
and rough-coated Collies is the result of autoimmune-mediated atrophic lymphocytic 
pancreatitis. Both the previous information on the inheritance of PAA and the current findings 
of marked T-lymphocytic inflammation when tissue destruction is in progress offered the 
main evidence of the autoimmune nature of the disease. The major role of cell-mediated 
cytotoxicity in tissue destruction was shown and the finding of autoantibodies further 
indicates an autoimmune nature of the disease.   
 
To study the response to long-term enzyme replacement treatment, a survey comparing the 
general well-being of 76 German shepherd dogs and rough-coated Collies treated for EPI and 
145 healthy control dogs of the same breeds was performed (Study IV). The response to 
treatment with nonenteric-coated enzyme supplements, powdered enzymes or raw chopped 
pancreas, was found to be good with half of the dogs and they did as well as the healthy dogs. 
Despite the basically similar treatment regimens, the responses to treatment varied 
considerably. A poor response was found in a fifth of the dogs showing several signs of EPI. 
Although dietary sensitivities were common, the need for dietary treatment was minimal. 
Short relapses of clinical signs may develop during long-term treatment and, besides enzyme 
treatment, antibiotics were occasionally administered to half of the dogs during treatment. 
However, the study indicates that permanent deterioration of the clinical condition in dogs 
with EPI during long-term treatment is uncommon. Thus, the prognosis for long-term enzyme 
replacement treatment is considered generally to be good. 
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2.  ABBREVATIONS 
 
CFU  colony forming units 
BSA  bovine serum albumin 
BT-PABA   N-benzoyl-L-tyrosyl-para-aminobenzoic acid 
GSD  German shepherd dog 
ELISA   enzyme-linked immunosorbent assay 
cEI   canine pancreatic elastase 1 
EPI   exocrine pancreatic insufficiency 
Ig  immunoglobulin 
IM  intramuscular 
IV  intravenous 
kD   kilodalton 
mAb  monoclonal antiboby  
MCT  medium chain triglyceride 
PAA   pancreatic acinar atrophy 
PBS   phosphate buffered saline 
p.o.  peroral 
RED   radial enzyme diffusion 
RER   rough endoplasmic reticulum 
RIA   radioimmunoassay 
RCC   rough-coated Collie 
SEPI  subclinical EPI  
SDS-PAGE   sodium-dodecyl-sulfate polyacrylamide gel electrophoresis 
SIBO   small intestinal bacterial overgrowth 
SST   soybean stimulation test 
cTLI   canine trypsin-like immunoreactivity 
TST   TLI stimulation test 
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4.  INTRODUCTION 
 
Chronic diseases of the exocrine pancreas may affect pancreatic secretory capacity and lead to 
inadequate production of pancreatic digestive enzymes and maldigestion signs typical for 
exocrine pancreatic insufficiency (EPI). EPI is a functional diagnosis based on measuring 
decreased pancreatic secretion capacity by a pancreatic function test (Freudiger 1971, 
Lankisch 1993, Williams 2000). 
 
In dogs, the possible underlying pathological processes that may result in clinical signs of EPI 
are pancreatic acinar atrophy (PAA), chronic pancreatitis and pancreatic neoplasia (Thordal-
Christensen and Coffin 1956, Geyer et al 1968, Holroyd 1968, Freudiger 1971, Rimaila-
Pärnänen and Westermarck 1982, Williams 2000). The prevalences of these different 
pancreatic diseases in dogs are difficult to assess because pancreatic morphological 
examination is needed for the specific diagnosis. However, pancreatic acinar atrophy is 
reported to be by far the most common cause of severe EPI in dogs. Chronic pancreatitis is 
less commonly diagnosed in dogs, although it has been reported to be a common cause of EPI 
in humans and in cats. Compared to PAA, the clinical signs of chronic pancreatitis in dogs are 
more non-specific gastrointestinal signs and are sometimes associated with signs of endocrine 
pancreatic dysfunction. In conjuction with pancreatic neoplasia, EPI is a rarely reported 
clinical sign (Thordal-Christensen and Coffin 1956, Geyer et al 1968, Holroyd 1968, 
Freudiger 1971, Rimaila-Pärnänen and Westermarck 1982, Hänichen and Minkus 1990, Steer 
et al 1995, Steiner and Williams 1997, Williams 2000).  
 
Canine PAA is a unique disease compared to PAA in other animals or humans (Eppig and 
Leiter 1977, Leiter and Cunliffe-Beamer 1977, Sidhu and Tandon 1995, Durie 1997). PAA 
has been studied extensively for the past 50 years, ever since it was reported by Thordal-
Christensen and Coffin (1956), Geyer et al (1968) and Holroyd (1968), and further described 
by Säteri (1975). Earlier, the terms juvenile atrophy, pancreatic collapse and pancreatic 
degenerative atrophy were also used to describe atrophic changes of the pancreas (Thordal-
Christensen and Coffin 1956, Holroyd 1968, Hill et al 1971, Rimaila-Pärnänen and 
Westermarck 1982). 
 
Characteristic for PAA is a selective destruction of the digestive enzyme producing acinar 
cells, which gives rise to severe maldigestion. An atrophied pancreas is thin and transparent 
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and the inflammatory reaction of atrophied parenchyma is usually absent or slight (Thordal-
Christensen and Coffin 1956, Geyer et al 1968, Hill et al 1971, Säteri 1975, Hashimoto et al 
1979, Rimaila-Pärnänen and Westermarck 1982). Although clinical signs and pathological 
findings of PAA are well-documented in literature, the etiopathogenesis of the atrophy 
process has remained obscure. PAA is most commonly found in young German shepherd 
dogs and rough-coated Collies. Of all the dogs diagnosed with clinical EPI, approximately 
70% were German Shepherd dogs and 20% rough-coated Collies (Freudiger 1971, 
Westermarck et al 1989, Hall et al 1991). The prevalence of PAA within these two breeds is 
estimated to be approximately 1% (Freudiger 1976, Westermarck et al 1989). 
 
German shepherd dogs and rough-coated Collies with PAA show similar genetic, clinical and 
pathological findings indicating a similar etiopathogenesis of the disease with these two 
breeds. In both breeds, PAA has shown to be inherited (Weber and Freudiger 1977, 
Westermarck 1980, Westermarck et al 1989, Moeller et al 2002). The problem with earlier 
etiopathogenetic studies is that they have been based on findings at the clinical phase of the 
disease. The exocrine pancreas has a large reserve secretory capacity and the clinical signs of 
maldigestion do not occur until 90% of secretory capacity is lost (DiMagno et al 1973). 
Severely atrophied acinar tissue has offered little in terms of etiopathogenesis.  
 
An ability to diagnose exocrine pancreatic dysfunction before the clinical phase would 
provide an opportunity for further study of the pathogenesis of the disease. Over the years, 
several studies have focused on developing a sensitive diagnostic test for exocrine pancreatic 
dysfunction in dogs. The value of these tests has rested on their ability to distinguish whether 
the signs of maldigestion are due to pancreatic disease or disease of the small intestine 
(Williams 2000). Today, the laboratory diagnosis of severe pancreatic dysfunction is reliable 
and simple and various function tests can be used to confirm the clinical diagnosis of EPI 
(Hill and Kidder 1970, Westermarck and Sandholm 1980, Batt and Mann 1981, Williams and 
Batt 1988, Spillmann et al 2001a). Further studies need to be carried out to ascertain whether 
these tests can also be used to detect early pancreatic dysfunction.  
 
The treatment of dogs with clinical disease and signs of EPI includes supplementing their 
food with pancreatic enzymes. Several studies have been made to discover the most suitable 
formular of pancreatic enzymes for dogs and to evaluate the role of dietary modifications in 
the treatment of EPI (Pidgeon 1982, Pidgeon and Strombeck 1982, Westermarck 1987, 
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Westermarck et al 1990, Simpson et al 1994, Westermarck et al 1995). When severe PAA is 
the cause for clinical EPI, lifelong enzyme replacement treatment is needed. To date, no 
comprehensive studies on response to and prognosis for long-term treatment are available. 
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5.  REVIEW OF LITERATURE 
 
5.1  Pancreatic acinar atrophy (PAA)  
 
5.1.1  Etiopathogenesis 
 
In pancreatic acinar atrophy (PAA), there is selective destruction of the digestive enzyme 
producing acinar cells. Loss of acinar tissue leads to inadequate secretion of pancreatic 
enzymes and thus to maldigestion signs typical for EPI. The endocrine pancreas is usually 
unaffected. Although PAA is a well-recognized disease, the etiopathogenesis of the atrophy 
process has remained obscure (Thordal-Christensen and Coffin 1956, Geyer et al 1968, 
Holroyd 1968, Freudiger 1971, Hill et al 1971, Säteri 1975, Hashimoto et al 1979, Rimaila-
Pärnänen and Westermarck 1982). 
 
PAA has been reported in many breeds, but increasingly in German shepherd dogs and, in 
Finland, also in rough-coated Collies (Clark 1960, Geyer et al 1968, Freudiger 1971, Hill et al 
1971, Säteri 1975, Prentice et al 1980, Rimaila-Pärnänen and Westermarck 1982, Williams 
and Batt 1988, Westermarck et al 1989, Hänichen and Minkus 1990, Boari et al 1994). PAA 
has been shown to be inherited both in German shepherd dogs and in rough-coated Collies. 
Pedigree analyses have suggested an autosomal resessive inheritance model (Weber and 
Freudiger 1977, Westermarck 1980, Westermarck et al 1989, Moeller et al 2002). 
Maldigestion signs typical for EPI appear usually at the age of 1 to 5 years and females and 
males are usually equally affected (Räihä and Westermarck 1989). 
 
Compared to other species, canine PAA is a unique disease. Naturally occurring pancreatic 
acinar atrophy has been reported in CBA/J mice (Eppig and Leiter 1977, Leiter and Cunliffe-
Beamer 1977). In humans, pancreatic acinar atrophy has been reported, but in association 
with multi-organ diseases such as Sjögren’s and Shwachman-Diamond syndromes (Sidhu and 
Tandon 1995, Durie 1997).  
 
Experimental studies have shown that acinar atrophy can be an end-result of various processes 
affecting the exocrine pancreas. These include pancreatic duct obstruction, ischemia, toxic 
situations, nutritional deficiencies or imbalances and defective secretory and/or trophic stimuli 
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(Herman and Fitzgerald 1962, Nevalainen and Janigan 1974, Fell et al 1982, Mizunuma et al 
1984, Oates et al 1986, Walker et al 1993, Tanaka et al 1994, Sidhu and Tandon 1995, 
Watanabe et al 1995). However, there is no evidence to support the involvement of these 
factors in naturally occurring PAA in dogs (Washabau 1995, Williams 2000). Congenital 
isolated deficiencies of pancreatic enzymes have been reported in humans (Durie 1997) but 
not in dogs. 
 
Because of the young age of the affected dogs, PAA has been also suggested to be a 
hypoplastic disease  (Holroyd 1968, Jubb 1983). There are some reports describing congenital 
exocrine, or compound exocrine and endocrine pancreatic hypoplasia in young puppies (Boari 
et al 1994, Neiger et al 1996, Boari et al 1997). However, based on the morphological 
findings at the end-stage phase of the disease, the general opinion has been that PAA is a 
degenerative disease (Thordal-Christensen and Coffin 1956, Freudiger 1971, Hill et al 1971, 
Säteri 1975, Hashimoto et al 1979, Pfister et al 1980, Rimaila-Pärnänen and Westermarck 
1982, Hänichen and Minkus 1990, Hellman and Loppnow 1991). Westermarck et al (1993a) 
followed morphological changes in the pancreas of a German shepherd dog puppy bred from 
parents with PAA. The results supported the hypothesis that acinar atrophy in German 
shepherd dogs is not hypoplastic, but due to a progressive and degenerative disease. 
Ultrastructural findings were first detected at the age of 6 weeks, but gross and histological 
abnormalities were seen only at the age of 2 years, when the clinical signs of EPI appeared 
and severe acinar atrophy was evident. The ultrastructural changes were degenerative without 
inflammation (Westermarck et al 1993a).   
 
Role of autoimmunity in the pathogenesis of PAA  
 
The possibility that acinar atrophy is a result of immune-mediated tissue destruction has 
previously received only scant attention and, to date, studies on the possible autoimmune 
nature of PAA are limited (Säteri 1975, Rimaila-Pärnänen and Westermarck 1982, Hellmann 
and Loppnow 1991, Simpson and Cobb 1998). 
 
Autoimmune diseases are multifactorial. Genetic suspectibility, environmental factors, and 
immunological abnormalities are all involved in this pathogenesis (Sinha et al 1990, Rose and 
Bona 1993, Janeway et al 1999). To prove that a disease is autoimmune-mediated, it must be 
shown that an adaptive immune response to a self-antigen causes the disease pathology. It is 
 15 
 
often difficult to find direct proof of autoimmunity and, often, only circumstantial evidence 
for the autoimmune nature of a disease can be shown. This evidence can include the following 
genetic, environmental, morphological and immunological factors that are characteristic for 
autoimmunity (Rose and Bona 1993, Janeway et al 1999).  
 
Genetic susceptibility to autoimmune disease involves many genes and the strongest 
associations have been seen with the major histocompatibility class II genotype (Sinha et al 
1990, Roep and De Vries 1992, Janeway et al 1999). Autoimmune diseases typically develop 
at a relatively young age and, because of hormonal influence, there is a female predominance 
(Sinha et al 1990, Janeway et al 1999).  
 
Environmental factors, either microbial or non-microbial, are usually needed to initiate a 
clinical autoimmune disease in genetically susceptible individuals (Janeway et al 1999). In 
many cases, because of difficulties in proving their presence and role, the triggering factors 
can only be suspected. Although an autoimmune disease usually seems to occur 
spontaneously, there is a strong association between infection and the onset of autoimmunity. 
This suggests that infectious agents, especially viruses, could have a critical role in the 
process (Schattner and Rager-Zisman 1990, Rose and Bona 1993, Janeway et al 1999).  
 
Autoimmune diseases may be divided into those mediated primarily by either cellular or 
humoral mechanisms (Sinha et al 1990, Roep and De Vries 1992, Rose and Bona 1993, 
Janeway et al 1999). Cell-mediated autoimmune reaction is characterized by lymphocyte 
infiltration into the organ, where tissue destruction is in progress (Carnaud and Bach 1993, 
Rose and Bona 1993). The evaluation of cell-mediated immune responses includes 
immunophenotyping the lymphocytes infiltrating the tissue and assessing the roles of different 
pathways and inflammatory cells (Sinha et al 1990, Janeway et al 1999). The basic screening 
of the humoral immune status includes serum protein electrophoresis, quantification of serum 
levels of different immunoglobulin classes or subclasses and serum autoantibody analyses 
(Sinha et al 1990). Most autoimmune diseases have a characteristic pattern of autoantibody 
production (Sinha et al 1990; Janeway et al 1999). Only a few autoantibodies such as anti-
glomerular basement antibodies in Goodpasture’s syndrome are the direct cause of clinical 
manifestations (Roitt el al 1998).  More commonly, the autoantibodies are used as markers for 
the disease and predictors of the clinical outcome (Rose 1989, Sinha et al 1990, Roep and De 
Vries 1992, Roep 1996, Janeway et al 1999). 
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In humans, an immune-mediated etiology has been proposed for some exocrine pancreatic 
diseases. Pancreatitis and pancreatic insufficiency of an autoimmune nature have been 
reported in association with multi-organ autoimmune diseases such as Sjögren’s syndrome, 
primary biliary cirrhosis and primary sclerosing cholangitis (Chari and Singer 1994, Ito et al 
1997). Antipancreatic antibodies have been detected in some forms of pancreatitis, thus 
suggesting the involvement of immunological mechanisms in their pathogenesis (Lendrum 
and Walker 1975, Lankisch et al 1981, Rumenssen et al 1985). Recently, the existence of 
autoimmune-mediated chronic pancreatitis in humans has been suggested (Yoshida et al 1995, 
Ito et al 1997, Okazaki et al 2000). Findings indicative of an autoimmune nature included 
hypergammaglobulinemia, antipancreatic autoantibodies (antilactoferrin against acinar cells 
and anticarbonic anhydrase II against ductal cells), pancreatic lymphocyte infiltration with 
fibrosis and treatment response to steroids (Yoshida et al 1995, Ito et al 1997, Okazaki et al 
2000). 
 
In dogs with PAA, earlier studies have shown genetic and morphological evidence suggestive 
of an immune-mediated disease (Freudiger 1971, Säteri 1975, Weber and Freudiger 1977, 
Westermarck 1980, Rimaila-Pärnänen and Westermarck 1982, Westermarck et al 1989). 
However, a problem has been the lack of morphological and immunological studies from the 
period when tissue destruction is in progress. Also, the possible contribution of different 
environmental factors, such as feeding, housing, training, stress or viruses in the pathogenesis 
of PAA has been proposed, but there are no comprehensive studies on their roles. A survey 
failed to show any common triggering environmental factors in the histories of dogs with EPI 
(Räihä and Westermarck 1989).  
 
Morphological studies in the clinical phase of PAA have shown the presence of lymphocytes 
and plasma cells in the atrophied pancreas, but their role has remained unclear because the 
samples were from the end-stage phase of the disease where the inflammatory reaction is 
usually mild (Hill et al 1971, Säteri 1975, Hashimoto et al 1977, Rimaila-Pärnänen and 
Westermarck 1982). Occasionally, larger amounts of lymphocytes have been detected in those 
clinical cases of PAA where tissue destruction was still partly in progress (Säteri 1975). This 
indicates that the cellular immunity may have become activated in the earlier phase of the 
atrophy process. Until now, only one study on the possible role of humoral immunity in the 
pathogenesis of PAA has been published. Simpson and Cobb (1998) reported circulating  
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pancreatic antibodies in dogs with EPI. However, since similar antibodies were found in 
healthy control dogs, their significance remained unclear. 
 
5.1.2  Clinical signs of exocrine pancreatic insufficiency (EPI)  
 
Clinical signs of the end-stage PAA are typical severe maldigestion signs of EPI (Freudiger 
1971, Räihä and Westermarck 1989). In the study by Räihä and Westermarck (1989), the 
most typical clinical signs of EPI included yellowish or grey faeces, increased faecal volume 
and defecation frequency, weight loss and flatulence. These signs were present in about 90% 
of dogs. Abnormally increased appetite, poorly digested, loose and pulpy faeces and 
occasional coprophagia were found in every other dog. Nervousness or aggressiveness was 
also reported in one third of the dogs. These were suspected as resulting from abdominal 
discomfort due to increased bowel movements and gas formation (Räihä and Westermarck 
1989). Severe watery diarrhoea is usually only temporary (Räihä and Westermarck 1989, 
Williams 2000). Prolonged and non-specific gastrointestinal signs may sometimes precede the 
typical clinical signs of EPI (Williams 2000). However, usually pre-existing gastrointestinal 
signs are not detected and signs of EPI develop within a short time frame in previously 
healthy animals (Räihä and Westermarck 1989). Skin disorders; poor coat and exemas have 
also been reported in dogs with EPI (Freudiger 1971). 
 
Although the clinical signs of EPI are considered typical, they are not pathognomonic for 
exocrine pancreatic dysfunction. The differential diagnosis includes diseases of the small 
intestine, causing signs of malabsorption or maldigestion (Säteri 1975, Rimaila-Pärnänen and 
Westermarck 1982, Räihä and Westermarck 1989, Williams 2000).  
 
5.1.3  Pathology  
 
PAA shows typical gross pathological findings, which may already be considered 
pathognomonic for the disease. Grossly, the pancreas is normal in length but thin and 
transparent. No fibrotic or hemorrhagic tissue is found. The normal glandular structure is 
hardly recognizable and the pancreatic ducts are clearly visible (Thordal-Christensen and 
Coffin 1956, Geyer et al 1968, Hill et al 1971, Säteri 1975, Hashimoto et al 1979, Rimaila-
Pärnänen and Westermarck 1982). Histologically, in the end-stage phase no normal acinar 
tissue is left, or if normal tissue is present, it is found in small isolated lobuli. Typically, the 
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normal acinar parenchyma is replaced by atypical tissue; disorganized small round cells with 
a central nucleus and light acidophilic, often slightly granular cytoplasm, and with prominent 
and dilated ductal structures. Fibrous tissue is not generally increased and in some cases the 
normal tissue has become replaced by adipose tissue. Inflammatory cells, lymphocytes and 
plasma cells may be found scattered or in small infiltrations among atrophied tissue (Thordal-
Christensen and Coffin 1956, Geyer et al 1968, Hill et al 1971, Säteri 1975, Hashimoto et al 
1979, Rimaila-Pärnänen and Westermarck 1982). The endocrine part of the pancreas in dogs 
with PAA is usually well preserved (Hill et al 1971, Säteri 1975), although some evidence for 
degenerative changes also in the endocrine cells has been reported (Pfister et al 1980, 
Hellmann and Loppnow 1991). 
 
Säteri (1975) divided histological findings in the clinical phase of PAA into three stages. In 
the first stage, some sparse normal acinar tissue was found among the atrophic parenchyma 
and, in the border zone between the normal and the atrophied tissue, the gradual transition of 
acinar cells was associated with lymphocytic infiltration. In the second stage, atypical 
atrophic tissue dominated but some normal acini were still found. The inflammatory reaction 
was, however, less intense than during the earlier stage. In the end-stage atrophy ductular 
structures were prominent but no normal tissue or inflammation was present. Hellmann and 
Loppnow (1991) divided PAA cases into those with focal atrophy, atrophy associated with 
lymphocytic inflammation, and advanced atrophy of end-stage phase. 
 
Only a few studies of the ultrastructural changes of PAA have been published. Hashimoto et 
al (1979) and Pfister et al (1980) described degenerative changes in the remaining acinar cells 
in the dogs with end-stage PAA. The findings were characterized by whorl formation and 
dilatation of the rough endoplasmic reticulum (RER) and loss of the zymogen granules. 
Westermarck et al (1993a) was dividing the progressive degenerative changes of acinar cells 
into four stages. The first stage showed the slight dilatation of RER. In the second stage RER 
became more dilated and disorganized, mitochondria and zymogen granules were larger than 
normal, and round condensing vacuoles were found in the cytoplasm. The nucleus was 
crenated and the chromatin condensed. In third stage dilatation of RER was increased, the 
nucleus was pyknotic, and there were extensive fusion of zymogen granules. In the final 
stage, acinar cells were necrotic. 
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Pathological findings in end-stage PAA are clearly different from those of chronic pancreatitis 
in dogs. Unlike in PAA, both the exocrine and the endocrine pancreas may become affected in 
chronic pancreatitis. Macroscopically, the pancreas is usually hard, shrunken and nodular, and 
there may be adhesions. Characteristic histological findings in chronic pancreatitis involve an 
increase in the interlobular and intralobular fibrosis and disorganized acinar lobuli, with or 
without inflammatory cells in the interstitium. Chronic pancreatitis may be classified as 
chronic interstitial pancreatitis, chronic fibrotic pancreatitis, pancreatic atrophic cirrhosis and 
pancreatic fibrosis (Thordal-Christensen and Coffin 1956, Geyer et al 1968, Holroyd 1968, 
Freudiger 1971, Rimaila-Pärnänen and Westermarck 1982, Hänichen and Minkus 1990). 
 
5.2  Evaluation of exocrine pancreatic function  
 
Either direct or indirect function tests are employed in evaluating the functional capacity of 
the exocrine pancreas. Direct tests measure the contents of pancreatic secretions in the 
duodenum, whereas indirect tests measure either pancreatic enzymes in the blood and faeces, 
or diminished digestive capacity (Lankisch 1993). The direct secretin-pancreozymin/ 
cholecystokinin stimulation test is considered the golden standard test for diagnosing and 
staging pancreatic dysfunction in humans. This test requires intubation of the patient, 
enterohormonal stimulation of the pancreas, and aspiration of the pancreatic juice from the 
duodenum to analyze the volume, bicarbonate and enzyme content. The particular advantage 
of direct tests is in diagnosing mild and moderate dysfunctions, but they are expensive, 
invasive, time-consuming, and impractical to perform (Lankisch 1993). Moreover, in 
performing direct tests on dogs, a general anaesthesia is needed. This may affect the secretory 
capacity of the pancreas and thus limit its value as a diagnostic test in canine pancreatic 
disease (Tiscornia et al 1972, Säteri 1975, Boden et al 1977). 
 
Indirect tests are a practical alternative for diagnosing EPI and their diagnostic value increases 
along with the severity of pancreatic dysfunction (Lankisch 1993). In dogs, the value of 
pancreatic function tests has relied mostly on their ability to distinguish whether the clinical 
maldigestion signs are due to exocrine pancreatic dysfunction or to a small intestinal disease 
(Williams 2000). Various indirect function tests; such as canine serum trypsin-like 
immunoreactivity (cTLI) measurement, faecal enzyme measurements (faecal proteolytic 
activity, faecal elastase), and a digestion test (serum BT-PABA; N-benzoyl-L-tyrosyl-para-
aminobenzoic acid) have been shown to be valuable in confirming the diagnosis of clinical 
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EPI (Hill and Kidder 1970, Westermarck and Sandholm 1980, Batt and Mann 1981, Williams 
and Batt 1988, Spillmann et al 2001a). 
 
5.2.1  Serum trypsin-like immunoreactivity (TLI) 
 
Recent years have seen the measurement of serum canine trypsin-like immunoreactivity 
(cTLI) by radioimmunoassay becoming one of the most commonly used pancreatic function 
tests to diagnose canine EPI. Serum TLI measurement is species- and pancreas-specific. It 
measures only pancreatic trypsin and trypsinogen that has entered the bloodstream directly 
from the pancreas (Williams and Batt 1983, 1988). Approximately 0.01% - 0.1% of the total 
daily secretion of trypsinogen leaks from acinar cells into the circulation (Borgström 1981). 
The reference range for cTLI in healthy dogs has been reported to be  >5.0 – 35.0 µg/L 
(Williams and Batt 1988). 
 
Serum cTLI measurement has proved to be very valuable in diagnosing severe exocrine 
pancreatic dysfunction in dogs. Abnormally low serum cTLI concentrations (< 2.5 µg/L) are 
found in association with the typical clinical signs of maldigestion. They are considered 
diagnostic for clinical EPI with high sensitivity and specificity (Williams and Batt 1988). 
Because trypsinogen does not need to be absorbed from the intestinal lumen, intestinal disease 
does not affect cTLI measurement. Enzyme replacement treatment does not affect serum cTLI 
measurement as the species-specific antibodies used in the assay do not cross-react 
immunologically with enzymes in supplementations and also because the absorption of the 
orally given enzymes into the bloodstream is limited (Williams and Batt 1988). 
 
It is recommended that serum samples for TLI measurement are taken after fasting for 8 to 12 
hours because a postprandial increase of serum trypsinogen levels, even slight and transient, 
may occur (Adrian 1980, Florholmen 1984, Reidelberg et al 1984, Williams 2000). A renal 
dysfunction associated with pancreatic disease could cause a rise in serum TLI because 
trypsinogen is eliminated by glomerular filtration (Geokas et al 1982, Williams 2000). In 
chronic pancreatitis, higher TLI values may be detected despite severe pancreatic dysfunction. 
This is because serum TLI can increase as a result of acute inflammatory attacks in the 
remaining exocrine tissue or because of pancreatic duct obstruction (Simpson et al 1989a, 
Keller 1990, Archer et al 1997).  
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In humans with chronic pancreatitis, the value of serum TLI for diagnosing mild or moderate 
dysfunction is considered questionable because TLI values overlapping with normal 
concentrations have been detected (Andrian 1980, Gullo et al 1980, Ruddell et al 1981). On 
the other hand, there have also been reports suggesting that serum TLI may be useful for an 
early diagnosis of exocrine pancreatic dysfunction both in humans and dogs. Andriulli et al 
(1981) reported that in human chronic pancreatitis, serum TLI concentrations correlated with 
results from the direct secretin-cholecystokinin test showing a parallel decrease with 
bicarbonate and enzyme secretion. In dogs, low serum cTLI values have reported to be the 
first marker of pancreatic dysfunction and low value may precede the clinical phase of EPI in 
dogs with PAA (Westermarck et al 1993a, Boari et al 1994). Simpson et al (1992) showed in 
dogs with partial pancreatectomy, and Westermarck et al (1993a) with naturally occurring 
PAA, that at the time the dogs showed no signs of EPI, the serum cTLI values were low but 
the other pancreatic function tests were still normal. Correlation analyses between serum cTLI 
and pancreatic weight have shown that about 25% of the normal pancreas mass is needed to 
maintain normal levels of serum cTLI (Simpson et al 1992).  
 
Occasionally, subnormal serum cTLI values, i.e 2.5 - 5.0 µg/L have been detected in dogs. 
When these dogs were retested the cTLI values were either suggestive of EPI or within 
normal limits (Williams and Batt 1988). Clinical studies of the significance of serum cTLI 
values between 2.5 and 5.0 µg/L are, however, lacking, and it is unclear whether these values 
are indicators of subnormal exocrine pancreatic function (Williams and Batt 1988). 
 
5.2.2  Serum TLI stimulation test (TST) 
 
To increase the value of serum TLI measurement for diagnosing and staging exocrine 
pancreatic dysfunction, TLI has been measured before and after pancreatic stimulation with 
either endogenous or exogenous pancreatic stimulants. In humans and in dogs, endogenous 
stimulation by food has not been found useful. Although an increase in serum TLI was 
observed, the response was slow and affected by dietary factors (Adrian 1980, Bonora et al 
1980, Spillmann 1995). A more significant response was achieved by exogenous stimulation 
with enterohormones, secretin and/or cholecystokinin (Adrian 1980, Bonora et al 1980, 
Vezzadini et al 1980, Spillmann 1995). Secretin is considered the main stimulant for 
bicarbonate fluid secretion and cholecystokinin for enzyme secretion, although some 
potentiated effect of two hormones has been reported (Beglinger et al 1984, Jo et al 1991).  
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In humans, the effect of secretin in increasing the serum TLI level has been suggested as 
being the result of an engorgement of the pancreatic ducts, which causes an increase in the 
intraductal pressure and regurgitation of trypsin into the bloodstream from the pancreas 
(Bonora et al 1980, Vezzadini et al 1980). In healthy humans, stimulation with secretin 
increased the serum TLI level, but no response to cholecystokinin stimulation was found 
(Adrian 1980, Bonora et al 1980, Vezzadini et al 1980). Vezzadini et al (1980) suggested that 
in patients with pancreatic disease the level of TLI response to secretin can depend on the 
stage of pancreatic dysfunction and could thus be used to assess the level of dysfunction. 
 
The value of the serum TLI stimulation test for diagnosing EPI in dogs was studied by 
Spillmann 1995. In this study cTLI was measured by ELISA. When the pancreas of healthy 
dogs was stimulated either by a combination of both secretin and ceruletide (cholecystokinin 
analogue) or by ceruletide alone, a significant response was detected. While a response to 
stimulation occurred in normal dogs, no response was detected in pancreaectomized dogs. 
The stimulation test could therefore be helpful in diagnosing cases with untypical pancreatic 
insufficiency, or in cases where fasting serum cTLI values are unequivocal (Spillmann 1995). 
Spillmann et al (2000) studied TLI stimulation also in cats. Ceruletide stimulation with 
normal cats showed an increase, but whether that is a diagnostic value for evaluating 
pancreatic function in cats remained open.  
 
5.2.3  Serum BT-PABA test 
 
The serum BT-PABA (N-benzoyl-L-tyrosyl-para-aminobenzoic acid) test measures indirectly 
the level of pancreatic enzyme activity in the small intestine. The test is based on the 
hydrolysis of a perorally given synthetic peptide, BT-PABA, by chymotrypsin in the 
duodenum. The free PABA can be measured either from plasma or urine after it has become 
absorbed from the intestine into the blood (Lankisch 1993). 
 
In dogs, the BT-PABA test has been shown to be valuable in diagnosing EPI (Batt et al 1979, 
Stradley et al 1979, Batt and Mann 1981, Zimmer and Todd 1985). The test is, however, 
impractical and the results may be affected by several factors such as delayed gastric 
emptying, hepatic or renal failure or by a severe malabsorptive small intestinal disease (Batt 
and Mann 1981, Zimmer and Todd 1985, Lankisch 1993). In humans, false normal BT-PABA 
results may be found in cases of mild or moderate pancreatic insufficiency (Lankisch 1993). 
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In dogs with an experimentally induced partial EPI, the serum PABA levels indicated a 
moderate dysfunction as the results were higher than in severe EPI but lower than in controls 
(Stradley et al 1979). On the other hand, when the BT-PABA test was compared to the serum 
cTLI measurement in dogs, the serum cTLI was found to be an earlier marker for EPI 
(Williams and Batt 1986, Westermarck et al 1993a). 
 
5.2.4  Faecal enzyme measurements  
 
Faecal proteolytic activity 
 
Low faecal proteolytic activity has been reported in dogs with severe EPI (Hill and Kidder 
1970, Burrows et al 1979, Westermarck and Sandholm 1980, Simpson and Doxey 1988, 
Williams and Reed 1990, Williams 2000). However, the reliability of different faecal 
proteolytic activity tests varies (Williams 2000). The gelatin digestion test is a simple 
qualitative/semiquantative method for detecting faecal proteolytic activity. The digestion of 
gelatin coating on X-ray film strips incubated in a faecal homogenate is suggestive of 
adequate faecal proteolytic activity. To increase the value of the X-ray film tests, it is 
important to standardize the technique by using X-ray films of the same type (Westermarck 
1982). More reliable, semiquantitative methods for measuring faecal proteolytic activity are 
the azocasein method (Hill and Kidder 1970) and radial enzyme diffusion (RED) into agar 
containing a casein substrate (Westermarck and Sandholm 1980).  
 
Faecal proteolytic activity should be measured in repeated samples because of the 
considerable daily variations in the results and because healthy dogs may occasionally pass 
faeces with low proteolytic activity (Hill and Kidder 1970, Westermarck and Sandholm 
1980). To prevent false negative results, faecal proteolytic activity has been measured after 
giving the dogs raw soybean in the food and by measuring activities in faecal samples from 3 
days (soybean stimulation test, Westermarck and Sandholm 1980). Pancreatic stimulation was 
shown to increase the sensitivities of both the X-ray and RED tests. After adding raw soybean 
to the food, a significant increase in faecal proteolytic activity was detected in apparently 
healthy dogs with low faecal protease activity, but not in dogs with severe EPI (Westermarck 
and Sandholm 1980). The mechanisms whereby soybean affects pancreatic secretion are, 
however, unclear. A feedback mechanism has been suggested; protease inhibitors in raw 
soybean are forming complexes with trypsin, thus decreasing the amount of proteases in the 
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intestine, and forcing the pancreas to further secrete (Anderson et al 1979). However, the 
natures of the feedback mechanisms in dogs are unclear and there are also reports that no 
pancreatic hypersecretion occurs after adding raw soybean to the food (Patten et al 1971).  
 
Faecal elastase 
 
A new faecal test for exocrine pancreatic dysfunction is the measurement of faecal elastase 
using the ELISA method. Elastase has been shown to have good intestinal stability, i.e. it does 
not degrade during the intestinal passage (Spillmann et al 2001b). Canine faecal elastase 
(cE1) is a species- and pancreas-specific test. No cross-reactions with bovine or porcine 
elastase have been detected. Thus the discontinuation of enzyme replacement therapy is not 
needed (Spillmann et al 2001b). The value of faecal elastase in confirming the diagnosis of 
clinical EPI has been shown both in dogs and in humans (Dominguez-Munoz et al 1995, 
Glasbrenner et al 1996, Löser et al 1996, Stein et al 1996, Spillmann et al 2001a).  
 
5.3  Treatment of EPI 
 
5.3.1  Enzyme replacement therapy 
 
Because the clinical signs of EPI are due to the inadequate production of digestive enzymes, 
the primary treatment is to supplement each meal with pancreatic enzyme preparations. 
Despite accurate enzyme supplementation, digestion capacity does not return to normal. Only 
a small portion of the orally-given enzymes are delivered functionally intact into the small 
intestine (DiMagno et al 1973, Pidgeon and Strombeck 1982, Westermarck 1987). Various 
pancreatic enzyme extracts are available and the best results in dogs have been achieved by 
using nonenteric-coated supplements. The highest enzyme activity in the duodenum has been 
achieved by supplemention with raw chopped pancreas or with powdered enzymes 
(Westermarck 1987). The value of enteric-coated supplements has been shown to be limited 
in dogs because of the delayed gastric emptying of the preparations (Marvola et al 1986, 
Westermarck 1987). Preincubation of enzymes in food before feeding and supplementation 
with bile salts or antacids have been tried in a bid to increase the efficiency of enzyme 
supplementation, but with no proven efficiency (Pidgeon and Strombeck 1982, Hall et al 
1991, Williams 2000). Inhibition of gastric acid secretion by the H2- antagonist, cimetidine, 
has shown some positive effects (Pidgeon and Strombeck 1982). Because of the expense of 
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H2-antagonists, their use is probably indicated only when the treatment response to enzymes 
alone is poor (Hall et al 1991, Williams 2000). Increasing the amount of enzyme supplement 
during the initial period of treatment or when there is an unsatisfactory response to treatment 
has been recommended (Hall et al 1991, Williams 2000). Other studies, however, have 
questioned the value of increased dosages (Pidgeon and Strombeck 1982, Westermarck 1987). 
 
5.3.2  Dietary modification 
  
Dietary modification with feeding a low fat, highly digestable and low fibre diet is commonly 
recommended for the treatment of EPI. However, clinical feeding studies have yielded 
controversial results of the actual benefits of using special diets (Pidgeon 1982, Batt 1990, 
Westermarck et al 1990, Hall et al 1991, Simpson et al 1994, Westermarck et al 1995).  
 
Because enzyme supplements alone are unable to restore normal fat absorption, a low fat diet 
has been considered necessary to achieve a favourable response to treatment. Perorally-given 
lipase is easily destroyed by the acid conditions in the stomach and up to 90% of lipase 
activity is lost before lipase reaches the duodenum (DiMagno et al 1973, Pidgeon and 
Strombeck 1982). Fat absorption may be affected also by the bacterial deconjugation of bile 
salts in a small intestinal disease, producing metabolites which in turn may result in diarrhoea 
(Batt 1990, Simpson et al 1994). Simpson et al (1994) reported that during initial enzyme 
treatment the low fat diet was important for a satisfactory response to treatment. Westermarck 
et al (1995) studied the effect of a low fat diet during the treatment by comparing the clinical 
signs when dogs were fed with their ordinary diet and a low fat diet. The results showed that 
feeding the low fat diet did not significantly alleviate clinical signs and was thus not found 
necessary.  
 
Highly digestable diets are recommended because undigested carbohydrates may produce 
osmotic diarrhoea and act as substrates for intestinal bacteria (Batt 1990). Feeding with a high 
fibre diet was found to increase faecal fat excretion and increase flatulence in human patients 
with EPI (Dutta and Hlasko 1985). In vitro studies have shown that some types of fibre may 
impair pancreatic enzyme activity (Dutta and Hlasko 1985). Clinical feeding studies in dogs 
with EPI have demonstrated that highly digestable, low fibre diets can alleviate clinical signs 
such as flatulence, borborygmi, increased faecal volume and defecation frequency 
(Westermarck et al 1990). Highly digestable diets may be of particular value in the initial 
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treatment until the nutritional status has improved and possible mucosal damage has been 
repaired. They may also be useful for dogs that fail to regain normal body weight with 
ordinary diets (Batt 1990, Williams 2000).  
 
To increase the energy uptake of dogs with EPI, medium chain triglycerides (MCT) have also 
been added to their food. A recent study found no obvious clinical benefits in the use of MCT 
(Rutz et al 2001). Dietary sensitivities may be a consequence of EPI. Therefore, hypoallergic 
diets may benefit some dogs with EPI, especially in the early stages of treatment (Batt 1990). 
 
5.3.3  Supportive therapy 
 
EPI may be associated with secondary problems that may worsen the clinical signs. These 
include small intestinal bacterial overgrowth, malabsorption of cobalamin and the coexistence 
of a small intestinal disease (Batt and Morgan 1982, Simpson et al 1989b, Williams et al 
1987, Rutgers et al 1995, Williams 2000).  
 
Small intestinal bacterial overgrowth (SIBO) is common in dogs with EPI not only before 
enzyme replacement treatment has been started, but also during treatment (Williams et al 
1987, Westermarck et al 1993b). An increased amount of substrates for bacteria in the small 
intestinal lumen, a lack of bacteriostatic factors of the pancreatic juice and changes in 
intestinal motility and immune functions are possible reasons for an abnormal accumulation 
of bacteria in the small intestine in dogs with EPI (Williams et al 1987, Simpson et al 1990, 
Johnston 1999).  
 
The diagnosis of SIBO is based on the bacterial culture of the duodenal juice. The criterium 
for SIBO has been proposed to be  > 105 CFU (colony forming units)/mL bacteria in the 
duodenum, although there is some disagreement on the definition of cutoff values (Batt 1983, 
Williams et al 1987, Simpson et al 1990, Westermarck et al 1993b, Delles et al 1994, Williard 
et al 1994, Rutgers et al 1995, Johnston 1999). Techical problems with taking duodenal juice 
samples have led to use indirect tests such as the measurement of serum folate and cobalamin, 
breath hydrogen testing and the measurement of deconjugated bile acids to detect SIBO (Batt 
and Morgan 1982, Johnston 1999, Melgarejo et al 2000). Serum folate and cobalamin 
measurements are based on the fact that some bacteria may synthesize folate and cause 
elevated serum folate levels and other bacteria may bind cobalamin and thereby prevent its 
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absorption, which decreases the serum levels. Although the tests measuring serum folate and 
cobalamin are practical, they lack sensitivity and specificity. Thus the finding of high serum 
folate and low cobalamin levels should be used only as evidence to support the occurrence of 
SIBO (Batt and Morgan 1982, Rutgers et al 1995, Johnston 1999). Recently it has been 
suggested that instead of SIBO, the term antibiotic responsive diarrhoea should be used when 
the clinical signs respond to antibiotic therapy, especially if there is no evidence of highly 
increased numbers of small intestinal bacteria (Johnston 1999).  
 
Antibiotics have been shown to be a valuable supportive treatment for EPI. They have been 
used especially during initial treatment in cases of poor treatment response to enzymes alone 
and if the clinical signs have recurred during enzyme treatment. Antibiotics reported as 
effective are tylosin, oxytetracyclin and metronidazole (Williams et al 1987, Hall et al 1991, 
Westermarck et al 1993b, Rutgers et al 1995, Williams 2000). 
 
Cobalamin deficiency has been reported in 36% to 76% of dogs with EPI (Batt and Morgan 
1982, Hall et al 1991, Williams 2000). This deficiency is partly due an increased uptake of 
cobalamin by intestinal bacteria and partly because of the lack of the pancreatic intrinsic 
factor, which has been shown to have a major role in the absorption of cobalamin. Enzyme 
supplementation alone has not been found to be helpful for increasing serum cobalamin 
levels. Parenteral cobalamin treatment is needed when low serum cobalamin values are 
detected. However, the clinical signs of cobalamin deficiency are still poorly documented in 
dogs suffering from EPI (Batt and Morgan 1982, Batt et al 1989, Simpson et al 1989b, 
Williams 2000). 
 
When treatment responses to enzymes and supportive therapies are insufficient, co-existing 
small intestinal disease and lymphoplasmacytic enteritis have to be suspected. To date, no 
comprehensive studies on EPI and associated small intestinal diseases have been published 
and recommendations for treatment with glucocorticoids are usually based only on personal 
observations (Williams 2000).  
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5.3.4 Prognosis 
 
When the clinical signs of EPI appear in dogs with PAA, the loss of functional pancreatic 
tissue is already almost total. The changes are considered to be irreversible, and lifelong 
enzyme replacement treatment is usually required (Williams 2000). The few studies on the 
prognosis of PAA and on the response to treatment with enzyme supplements have focused 
on the response to initial treatment (Hall et al 1991, Simpson et al 1994). The overall response 
to enzyme treatment has been reported to be good in 64% and poor in 17% of cases, when the 
effect of treatment was assessed according to its ability to decrease diarrhoea and polyphagia 
and increase bodyweight (Hall et al 1991). In many dogs, a resolution of these signs could be 
found during the first weeks of treatment (Hall et al 1991, Williams 2000).  
 
A reduction in enzyme doses may be tried after an initial response to treatment has been 
achieved (Hall et al 1991, Williams 2000). Decreasing the enzyme dose to 50% did not result 
in a significant deterioration of the clinical signs (Westermarck et al 1995). Although lifelong 
treatment is indicated for most dogs with PAA, there are also exceptions. In two dogs with 
clinical signs of EPI, the discontinuation of enzyme supplements after a good initial treatment 
response did not cause a recurrence of clinical signs (Westermarck and Rimaila-Pärnänen 
1989b). Although these dogs had apparent pathological changes typical for PAA, some 
pancreatic tissue with reserve secretory capacity had remained and continuous enzyme 
replacement treatment was unnecessary. 
 
Based on the survey by Hall et al (1991), during the first two years after the diagnosis of EPI, 
approximately 30% dogs were euthanized, some of the dogs immediately after diagnosis was 
established. The principal reasons for euthanasia were a failure to respond to treatment, 
refusal by the owners to continue treatment and the high cost of treatment (Hall et al 1991). 
Westermarck and Rimaila-Pärnänen (1989a) reported about severe, but rare complication of 
EPI; mesenteric torsion. This is probably caused by disorders in intestinal motility and by 
excessive intestinal gas.  
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6.  AIMS OF THE STUDY 
 
The aims of the current study were 
 
      I   to study the etiopathogenesis of PAA  
 
a) setting up a diagnostic method to detect exocrine pancreatic dysfunction 
before end-stage PAA and before the clinical signs of EPI have developed,  
 
b) analyzing morphological changes in the exocrine pancreas during the 
progression of PAA, 
 
c) assessing the roles of the cellular and humoral immune mechanisms in the 
pathogenesis of PAA and  
 
     II   to study the response to long-term enzyme replacement treatment in dogs with 
clinical signs of EPI   
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7.  MATERIALS AND METHODS 
 
7.1  Animals 
 
Studies I-III were set up to study the etiopathogenesis of PAA and to find a method for early 
detection of EPI, in the subclinical phase. Subclinical EPI (SEPI) was suspected in the dogs 
with a serum cTLI concentration < 5.0 µg/L (normal range, > 5.0 – 35.0 µg/L, Williams and 
Batt 1988), but no typical clinical signs of EPI. During 1995-1997, 1,236 serum samples were 
measured for cTLI in the Veterinary Laboratory Vetlab, Tampere, Finland. Of these samples, 
187 were abnormally low (< 2.5 µg/L) and 76 subnormal 2.5 - 5.0 µg/l. Screening the data 
from 158 dogs with serum cTLI < 5.0 µg/L revealed 44 dogs with low serum cTLI 
concentration but no clinical signs of EPI (Study I). Nine of the 44 dogs had cTLI 
concentration < 2.5 µg/L but no signs of EPI. In 35 dogs with various clinical histories the 
cTLI values were subnormal. These 44 dogs were considered as suspected of SEPI and were 
subjected to further studies (Tables 1, 2, Pages 39,40). Based on the pancreatic morphological 
findings (Study I and II), the diagnosis of SEPI/partial PAA was made in 13 the dogs (Tables 
1-2, Pages 39,40). Findings of the dogs with SEPI were compared to those of the control dogs 
and the dogs with clinical signs of EPI (Study I, II and III). The control dogs (n=18) were 
apparently healthy dogs with a single serum cTLI concentration within the normal range       
(> 5.0 – 35.0 µg/L). A morphological examination of the pancreas by autopsy was performed 
in five laboratory beagles revealing a normal pancreas. Dogs with clinical EPI (n=23) had 
clinical maldigestion signs typical for EPI (weight loss, polyphagia, loose and voluminous 
faeces). The dogs had a single abnormally low serum cTLI (< 2.5 µg/L) value or low faecal 
proteolytic activity (Westermarck and Sandholm 1980) indicating severe pancreatic 
dysfunction. In 12 dogs, pathological examination verified end-stage PAA. The study was 
approved by the Ethical Committee of Faculty of Veterinary Medicine, University of 
Helsinki, and the owners allowed to use their pets in the study.    
 
Study IV was set up to study the response to long-term enzyme replacement treatment in dogs 
with clinical EPI. The survey included 76 German shepherd dogs and rough-coated Collies 
with clinical EPI and 145 apparently healthy control dogs of the same breeds (Table 1, Page 
39). EPI was diagnosed on the basis of clinical signs typical for EPI and on low serum cTLI 
concentrations (< 2.5 µg/L). Data on the control dogs was received from the breed 
associations. Based on the information received from the owners, the study included those 
control dogs that had no chronic illness necessitating continuous medication. 
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7.2  Methods   
 
7.2.1  Pancreatic function tests 
 
7.2.1.1  Serum cTLI  (I, II, III, IV) 
 
In all serum samples measured for canine trypsin-like immunoreactivity, cTLI, a  
radioimmunoassay (Double Antibody Canine TLI, Diagnostic Products Corporation, Los 
Angeles, CA) was used (Williams and Batt 1988). Serum samples were collected after an 
overnight fast and stored at -20oC before analysis. In Study I, repeated cTLI measurements 
was performed to 44 dogs with suspected SEPI. 
 
7.2.1.2  Serum TST  (I) 
 
TST was performed on 10 controls, 12 dogs with SEPI and 6 dogs with clinical EPI. Serum 
TST was modified from the test described by Spillmann (1995). After overnight fasting, 
serum samples for cTLI assay were collected from each dog. Immediately thereafter, the 
pancreas was stimulated by the intravenous administration of both secretin (1.0 IU/kg; 
Secretin, Ferring Pharmaceuticals, Malmö, Sweden) and cholecystokinin (1.0 IU/kg; 
Cholecystokinin, Ferring Pharmaceuticals, Malmö, Sweden) diluted 1:10 with NaCl and 
infused over 1-2 minutes. A serum sample for the second cTLI-assay was collected 20 
minutes after stimulation.  
 
7.2.1.3  Serum BT-PABA test  (I) 
 
The serum BT-PABA (n-benzyol-l-tyrosyl-para-aminobenzoic acid) test was performed on 4 
dogs with SEPI. After overnight fasting, the dogs were given 16.5 mg/kg BT-PABA in 10 ml 
water/kg p.o., and one and two hours later serum samples were taken and analyzed for PABA 
(Batt and Mann 1981). 
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7.2.1.4  Faecal proteolytic activity  (I) 
 
Faecal proteolytic activity measurement after soybean stimulation (soybean stimulation test, 
STT) was performed on 10 dogs with SEPI. The dogs were fed raw soybean mixed with food 
for 4 days and faecal samples were collected on days 2, 3 and 4. Faecal proteolytic activity 
was measured by both radial enzyme diffusion (RED) in a calcium caseinate agar and by an 
X-ray film test (Westermarck and Sandholm 1980). 
 
7.2.2  Pancreatic biopsy  (I, II,) 
 
A pancreatic biopsy was taken by laparotomy in 11 dogs with suspected SEPI and 3 dogs with 
clinical EPI. For laparotomy, the dogs were premedicated with medetomidine (40 µg/kg IM) 
and anaesthesia was induced with propofol (0.5-1.0 mg/kg IV) and maintained on 1% to 2% 
halothane. The pancreas was evaluated grossly by two observers. A pancreatic biopsy < 5 mm 
in diameter was taken from the caudal part of the pancreas by ligation with 3-0 absorbable 
monofilament suture material. All dogs were given prophylactic antibiotics (amoxicillin 20 
mg/kg) and analgesics (buprenorphine 0.01 mg/kg) during surgery. Recovery from surgery 
was uncomplicated in all dogs. A biopsy was taken by autopsy from 5 control dogs, 2 of 13 
dogs with suspected SEPI and 9 of 12 dogs with clinical EPI. 
 
7.2.3  Histopathology  (II) 
 
Pancreatic biopsies of 5 control dogs, 13 dogs with SEPI and 10 dogs with clinical EPI were 
studied histopathologically. The biopsies (2-3 mm in diameter) were fixed in 10% neutral 
buffered formalin, processed routinely, and embedded in paraffin. Sections (4 mm) were 
stained with hematoxylin-eosin.  
 
Two observers performed blind histological evaluation. The following findings were 
evaluated: histologically normal versus affected parenchyma, degree of inflammation, 
inflammatory cell pattern (infiltrative, diffuse, focal, multifocal), localization of inflammatory 
cells and inflammatory cell types, localization and degree of fibrous connective tissue.  
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7.2.4  Ultrastructure  (II) 
 
Pancreatic biopsies from 5 control dogs, 11 dogs with SEPI and 4 dogs with clinical EPI were 
studied by electron microscopy. Immediately after the pancreatic biopsy, parts of the biopsies 
were cut into pieces of 0.5 to 1 mm3 and fixed in 2.5% glutaraldehyde in 0.1 M sodium 
phosphate buffer (pH 7.3). Afterwards, the pieces were postfixed in osmium tetroxide and 
embedded in epoxy resin. For light microscopic studies, the semithin sections (1 mm) were 
cut and stained with 1% toluidine blue to select appropriate areas for ultrathin sections. The 
ultrathin sections were cut on the basis of light microscopic findings. The sections were 
placed on grids, stained with uranyl acetate and lead citrate and were examined under a Jeol 
JEM 100 S transmission electron microscope. 
 
7.2.5  Cell-mediated immunity  (II, III)    
 
7.2.5.1  Immunohistochemical study   
 
Formalin-fixed pancreatic biopsies were used for immunohistochemistry in order to study the 
presence of T-lymphocytes, insulin-producing Langerhans β-cells and macrophages. 
Formalin-fixed and paraffin-embedded pancreatic biopsies were cut into sections of 4 mm, 
and deparaffinized.  
 
T-lymphocytes 
 
To study the presence of T-lymphocytes, immunohistochemical studies were performed with 
biopsies obtained from 5 control dogs, 12 dogs with SEPI and 8 dogs with clinical EPI. 
Indirect immunoperoxidase staining was performed using a commercial streptavidin-biotin kit 
(DAKO LSAB Kit, Peroxidase; Dako Corporation, Carpinteria, CA). The sections were 
treated with 3% hydrogen peroxidase to inhibit the endogenous peroxidase. After blocking, 
the sections were incubated with a 1:50 polyclonal rabbit anti-human CD3 (cross-reacting 
with dog CD3) for 30 minutes (DAKO rabbit anti-human CD3, Code A454) to detect T-cells. 
Staining was done using the biotinylated secondary antibody and peroxidase-labelled 
streptavidin and completed after incubation with a substrate-chromogen solution (DAKO 
AEC Substrate System, Code K696). The sections were counterstained with Mayer's 
hematoxylin.   
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Double staining for T-lymphocytes and insulin producing β - cells  
 
Double staining to detect T-lymphocytes and endocrine Langerhans β-cells was performed on 
sections from one control dog, 5 dogs with SEPI and one dog with clinical EPI. Staining was 
initially performed as described above with a 1:50 anti-human CD3 antibody, followed by 
incubation with a secondary antibody (DAKO Multilink, Code E453), peroxidase-conjugate 
(DAKO ABComplex/ HPR Code K355) and a substrate-chromogen solution (DAKO DAB 
Chromogen tablets, Code S3000). Insulin staining was done with a 1:200 anti-porcine insulin 
antibody for 30 minutes (DAKO guinea pig anti-porcine insulin, Code A464), a secondary 
antibody (DAKO Multilink), an alkaline phosphatase-conjugate (DAKO ABComplex/AP, 
Code K376) and a substrate-chromogen solution (DAKO Fast Red, Code K597). The sections 
were counterstained with Mayer's hematoxylin.   
 
Macrophages 
 
The presence of macrophages was studied in 4 control dogs, 8 dogs with SEPI and 4 dogs 
with clinical EPI. Indirect immunoperoxidase staining was performed by using a DAKO 
EnVision+, Peroxidase Kit (DAKO). After treatment with a peroxidase blocking agent, the 
sections were incubated with a 1:800 diluted rabbit anti-human lysozyme antibody for 30 
minutes (DAKO rabbit anti-human lysozyme), followed by incubation with the peroxidase 
labelled polymer conjugated to secondary antibody. Staining was completed by incubation 
with a DAB substrate-chromogen solution.  Counterstaining was done with Mayer's 
hematoxylin.   
 
CD4+ helper T-cells, CD8+ cytotoxic T-cells, B-lymphocytes 
 
Immunohistochemical analysis of the cryostat sections of pancreas was employed to detect 
CD4+ T-helper cells, CD8+ cytotoxic T-cells, B-lymphocytes and plasmacells. The pancreas 
biopsies (2-3 mm in diameter) from 5 control dogs, 9 dogs with SEPI and 4 dogs with clinical 
EPI were frozen in liquid nitrogen and stored at -80°C. Serial cryostat sections (4 µm) were 
prepared and stored at –20°C. Before use, the sections were kept at room temperature (22°C) 
for 15 minutes, fixed in cold acetone (+4 to +8°C) for 10 min and air dried at 22°C for 10 
minutes. 
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Indirect immunoperoxidase staining was performed by using a commercial streptavidin-biotin 
kit (DAKO LSAB Kit, Peroxidase; DAKO). After blocking, the sections were incubated for 
30 minutes at 22°C with one of the following primary antibodies: mouse anti-dog CD4 and 
CD8; diluted 1:20 (from Dr. Peter Moore, Leukocyte Antigen Biology Lab, University of 
California, Davis, CA) and mouse anti-human CD79; diluted 1:50 (DAKO). The bound 
antibodies were detected with the biotinylated secondary antibody, peroxidase-labelled 
streptavidin, and a substrate-chromogen solution (DAKO AEC Substrate System). The 
sections were counterstained with Mayer's hematoxylin.   
 
Evaluation of immunohistological findings 
 
Two observers performed blind evaluation. Estimates of the degree, pattern and localization 
of CD3-positive cells were obtained by comparing the CD3-stained slides with the 
hematoxylin-eosin-stained slides. The number and distribution of macrophages were 
estimated in non-affected, inflamed and atrophied tissues. The number of cells staining 
positively with CD4, CD8 and CD79 mAbs were counted using a light microscope at 400 x 
magnification. The average number of positive cells in 15 to 30 representative fields of 0.79 x 
0.79 mm were counted for each staining. The intensity of lymphoid cell infiltration was 
estimated by semiquantitative analysis as follows:  0= no positively staining cells, 1+=< 5 
positive cells; 2+= 5 to 20 positive cells; 3+ = 20 to 50 positive cells; 4+ = > 50 positive 
cells/field. The inflammatory cell pattern was described as: scattered= infiltrating single cells; 
multifocal= numerous separate cellular infiltrates; focal= larger lymphoid cell aggregates with 
or without resemblance of a lymphoid follicle; diffuse = extensive cell infiltration. 
  
7.2.6  Humoral immunity  (III) 
 
7.2.6.1  Serum protein electrophoresis  
 
The serum samples from 10 control dogs, 8 dogs with SEPI and 6 dogs with clinical EPI were 
analyzed by standard agarose gel electrophoresis (Beckman Paragon, Beckman Instruments, 
Fullerton, CA). 
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7.2.6.2  Serum immunoglobulin quantification  
 
Serum IgG, IgM, IgA concentrations from 5 control dogs, 6 dogs with SEPI and 8 dogs with 
clinical EPI were determined using a single radial immunodiffusion method (SRID Kit, 
Canine IgG, IgM, IgA, Veterinary Medical Research and Development, Pullman, WA) and 
standards provided by the manufacturer. 
 
7.2.6.3  Serum autoantibody detection  
 
Immunofluorescence microscopy   
 
Indirect immunofluorescence microscopy was used to search for any pancreas-specific and 
non-organ specific antibodies in the sera from 13 control dogs, 9 dogs with SEPI and 10 dogs 
with clinical EPI. Cryostat sections (4 µm) were prepared from tissue samples from a non-
diseased dog's pancreas, liver, kidney, gastric mucosa, oesophagus, adrenal gland and 
submandibular salivary gland. Before use, the sections were put in room temperature (22°C) 
for 15 minutes, fixed in acetone (+4 to +8°C) for 10 min and air dried at 22°C for 10 minutes. 
 
The sections were treated with 3% BSA in phosphate-buffered saline (PBS) for 5 minutes to 
prevent non-specific binding reactions. The sera were diluted 1:2 with 3% BSA/PBS to detect 
pancreatic antibodies and 1:5 to detect non-organ specific antibodies. The sections were 
incubated with serum samples for 30 minutes at 22°C. After washing, the fluorescein-
conjugated secondary antibody (goat anti-dog IgG, Southern Biotechnology Associates, 
Birmingham, AL), diluted 1:20 was added and incubated for 30 minutes. After washing, the 
sections were mounted with the Mowiol mounting medium and analyzed under an Olympus 
BX50-FLA microscope using a filter specific for fluorescein.      
 
Antinuclear antibodies were analyzed using human epithelioid cells (HEp-2 cells, American 
Type Culture Collection, Bethesda, MD). The cell plates were incubated with sera diluted 
1:20 with PBS for 30 min at 22°C. After washing, the fluorescein-conjugated secondary 
antibody (goat anti-dog IgG) diluted 1:20 was added and incubated for 30 min at room 
temperature. After washing, the samples were analyzed as above. 
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Immunoblotting analysis   
 
The Western blotting method was used to analyze potential pancreas-specific antibodies in 
sera from 7 control dogs, 7 dogs with SEPI and 7 dogs with clinical EPI. A pancreatic tissue 
sample from a non-diseased dog was homogenized, heated to 56°C for 5 minutes and 
solubilized in SDS buffer in the presence of a non-reducing buffer or reducing buffer 
containing β-mercaptoethanol (10%). Proteins in the pancreatic homogenates were separated 
by SDS-PAGE in 12.5% gels (Mini-PROTEAN II Dual Slab Cell, Bio Rad Laboratories, 
Richmond, CA) using molecular weight markers from Biorad (SDS-PAGE Standards, Low 
Range). For immunodetection, the separated proteins were transferred electrophoretically 
from the gel into a nitrocellulose membrane. The nitrocellulose strips were incubated at 22°C 
overnight with the blocking solution (1% BSA in Tris-saline-Tween [Tween-20, 0.05 %]) 
and, thereafter, with the sample sera diluted 1:100 with 1% BSA-Tris-saline-Tween for 1 hour 
at 22°C. After washing, the strips were incubated for 1 hour at 22°C with alkaline 
phosphatase-conjugated secondary antibody (Rabbit anti-dog IgG, Jackson ImmunoResearch 
Laboratories, West Grove, PA) diluted 1:500 with Tris-saline-Tween. After further washing, 
staining was completed using a chromogen substrate for alkaline phosphatase (AP Color 
Development Reagent BCIP and NBT, Bio Rad). Samples were analyzed after a short rinse in 
water. 
 
7.2.7  Survey of the response to long-term enzyme replacement treatment  (IV) 
  
Questionnaires were sent to the 145 owners of dogs with clinical EPI (German shepherd dogs 
or rough-coated Collies) and to 211 owners of clinically normal control dogs (German 
shepherd dogs or rough-coated Collies). Dogs with EPI had been given dietary enzyme 
supplements for at least 4 months. Detailed questions about current clinical signs and dietary 
habits were asked. Owners were asked to assess severity and generality of gastrointestinal and 
dermatological signs, using criteria provided with the questionnaire. Owners of the dogs with 
EPI were also asked about enzyme supplements, dietary modification and adjunctive 
treatments during the initial and long-term treatment periods. 
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7.2.8  Statistical methods 
 
Study I:  In TST, a t-test for paired samples was used to study the significance of the TLI 
response in each group. Differences between the groups were tested with Student's t-test for 
unequal variances. A p-value of < 0.05 was considered significant.  
Study III: One-way analysis of variance followed by Tukey's test was used to study the 
differences in serum electrophoretic fractions and serum immunoglobulin levels between the 
three groups: control dogs, dogs with SEPI and dogs with clinical EPI. A p-value of < 0.05 
was considered significant. 
Study IV:  Multinomial logit models and cross tabulations followed by χ2 testing were used to 
compare the relative frequency distributions of gastrointestinal tract and dermatological signs, 
feeding regimens and dietary intolerances between EPI- and control-group dogs. Eleven 
gastrointestinal signs (Table 3, Page 51) were classified as typical for dogs with EPI on the 
basis of clinical signs of the dogs in Study IV and information in the previous report (Räihä 
and Westermarck 1989). Prevalences of typical EPI signs were compared between the 
different groups by means of logit models and cross tabulations followed by χ2 testing. The 
models were evaluated by the use of likelihood ratio goodness-of-fit statistic. Tukey’s test 
was used to compare the number of typical EPI signs among the groups of dogs treated for 
various periods. A p-value of < 0.05 was considered significant. 
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Table 1. Study categories and characteristics of animals in the different study groups 
 
Study Purpose of the study  Study group Breed, age, sex Criteria 
I Diagnostic study for  
subclinical EPI/partial PAA 
 
Suspected 
subclinical EPI 
n=44 
27 GSD, 7 RCC, 
10 other breeds  
Mean age 3.3 years  
25 M, 19 F 
No clinical signs of EPI 
Single cTLI < 5.0µg/L 
PAD (n=12) 
  
 
 
Clinical EPI 
n=6 
 
5 GSD, 1 RCC 
Mean age 3.5 years  
4 M, 2 F 
 
Typical clinical signs of EPI 
Single cTLI < 2.5µg/L 
PAD (n=3) 
   
Control dogs 
n= 10 
 
10 beagles,  
Mean age 1 years  
6 M, 4 F 
 
Apparently healthy 
Single cTLI > 5.0–35.0 µg/L 
PAD (n=5) 
 
II 
 
Morphological  
Immunological study 
 
Subclinical EPI/ 
Partial PAA 
n=13 
 
11 GSD, 2 RCC 
Mean age 3.2 years 
8 M, 5 F 
 
No clinical signs of EPI 
cTLI repeatedly < 5.0µg/L * 
 
 
       Clinical 
EPI/PAA 
n=11 
 
 
10 GSD, 1 RCC 
Mean age 6.3 years 
7 M, 4 F 
Typical clinical signs of EPI 
Single cTLI < 2.5µg/L (n=5) 
Low faecal prot. activity (n=6)
 
  Control dogs 
n=5 
5 beagles 
Mean age 1 year  
3 M, 2 F 
Apparently healthy 
Single cTLI > 5–35.0µg/L 
 
III Immunological study 
 
Subclinical EPI/ 
Partial PAA 
n=12 
10 GSD, 2 RCC 
Mean age 3 years  
7 M, 5 F 
No clinical signs of EPI 
cTLI repeatedly < 5.0µg/L 
PAD (n=12) 
  Clinical EPI 
n=13 
11 GSD, 2 RCC 
Mean age 3.7 years  
11 M, 2 F 
Typical clinical signs of EPI 
Single cTLI < 2.5 µg/L (n=11)
Low faecal prot. activity (n=2)
PAD (n=4) 
 
 
  
Control dogs 
n=13 
 
8 GSD, 5 beagles; 
Mean age 1.1 year (n=8) 
9 M, 4 F 
 
Apparently healthy 
Single cTLI > 5.0–35.0µg/L 
PAD (n=5) 
 
IV 
 
Treatment study 
        
 
Clinical EPI 
n=76 
 
45 GSD; age 5.3 years  
31 RCC; age 4.6 years 
45% M, 55 % F 
 
Typical clinical signs of EPI 
cTLI < 2.5 µg/L 
 
   
Control dogs 
n=145 
 
72 GSD; age 3.5 years 
73 RCC, age 3.6 years 
46 % M, 54% F 
 
 
Apparently healthy 
 
EPI= exocrine pancreatic insufficiency; PAA= pancreatic acinar atrophy; Breeds; GSD=German shepherd dog; 
RCC=rough-coated Collie;M=male, F=female; cTLI= fasting serum canine trypsin-like immunoreactivity 
measurement (RIA) Criteria: based on clinical status, serum cTLI or faecal proteolytic activity measurement, and 
PAD results (pathologic-anatomic diagnosis). *In one dog with partial PAA (Study II, III), a single low cTLI 
value was taken 
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Table 2. A flowchart showing the diagnostic methods of the Studies I-III. 
 
 
cTLI= fasting serum canine trypsin-like immunoreactivity (radioimmunoassay) 
             * For one of the dogs, a single cTLI measurement (< 5.0 µg/L) was taken 
4 dogs 
Clinical signs of EPI 
cTLI < 2.5µg/L 
 
20 dogs 
No clinical signs of EPI 
cTLI < 5.0 µg/L (1.0- 4.9 µg/L) 
20 dogs 
No clinical signs of EPI 
cTLI > 5.0 µg/L 
 
Retesting of cTLI 
Pancreatic morphological 
examination 
 13 dogs*
 
Study II 
Morphological study 
              13 dogs  Histology 
      11 dogs  Ultrastructure 
 
                 Study II-III 
Immunological studies 
Cellular immune response 
 
12 dogs immunophenotyping tissue 
inflammatory cells 
Humoral immune response 
 
 8 dogs serum protein electrophoresis 
 6 dogs serum immunoglobulins 
 9 dogs serum autoantibodies 
Study I 
44  dogs 
No clinical signs of EPI 
cTLI < 5.0 µg/L 
No further studies No further studies 
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8. RESULTS 
 
8.1  Diagnosis of subclinical EPI caused by partial PAA (I) 
 
8.1.1  Serum cTLI 
 
To study the value of serum cTLI measurement in diagnosing exocrine pancreatic dysfunction 
in the subclinical phase, 44 dogs with suspected subclinical EPI were retested for cTLI. The 
dogs had a low serum cTLI < 5.0 µg/L but not typical signs of EPI. 
 
In retesting, cTLI was repeatedly low (<5.0 µg/L) in 20/44 dogs (16 German shepherd dogs, 4 
rough-coated Collies; ages 1 to 8 years, mean 3.7 years; 11 males and 9 females). Clinically, 
15 dogs had no gastrointestinal signs at the time of retesting, and 5 dogs had signs not typical 
for EPI (e.g., occasional diarrhoea, food intolerance). Laparotomy and pancreatic biopsy were 
performed on 12/20 dogs (10 German shepherd dogs and 2 rough-coated Collies, aged 1 to 8 
years; mean 3.4 years, with 7 males and 5 females). At the time of laparotomy, serum cTLI of 
these dogs ranged from 1.0 to 4.1 µg/L (mean, 2.7 µg/L). The time periods between the first 
cTLI measurement and laparotomy ranged from 1 to 12 months (mean, 4.6 months). In all 12 
dogs the laparotomy verified partial acinar atrophy (detailed results are shown in 8.2.). 
Because the dogs with partial PAA did not show signs typical for EPI, they were diagnosed as 
having subclinical EPI (SEPI).  
 
By the time of retesting, clinical EPI was confirmed in 4/44 dogs (3 German shepherd dogs 
and 1 Chow Chow; aged 1 to 5 years, mean 2.5 years; all females). In retesting, these dogs 
showed clinical signs of EPI and serum cTLI concentrations ranged from 0.6 to 0.9 µg/L 
(mean, 0.7 µg/L). The times between the TLI measurements ranged from 2 to 12 months 
(mean, 5.5 months). No further studies were performed on these dogs. 
 
Retesting showed cTLI values in the normal range in 20/44 dogs (8 German shepherd dogs, 3 
rough-coated Collies, 2 Great Danes, 2 Chow Chows, 5 representing different breeds; aged 1 
to 9 years, mean 4.2 years; 14 males, 6 females). Serum cTLI concentrations ranged from 5.2 
to 28.4 µg/L (mean, 10.5 µg/L). The time intervals between the measurements ranged from 1 
to 27 months (mean, 18.4 months). Clinically, 13 dogs showed no gastrointestinal signs at the 
time of retesting, 6 dogs had occasional gastrointestinal signs and 1 dog had chronic 
diarrhoea. No laparotomy was performed on any of these dogs. 
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8.1.2  Serum BT-PABA and faecal proteolytic activity  
 
An evaluation was made of the value of serum BT-PABA and faecal proteolytic measurement 
in diagnosing subclinical EPI. The results of serum BT-PABA testing were subnormal in 3 of 
4 dogs with SEPI and normal in one dog. Mean peak PABA level was 20.5 µmol/L (range, 
11.5 to 32.2 µmol/L; normal range, > 25 µmol/L). The results of faecal proteolytic activity 
measurement by SST showed normal faecal proteolytic activity (peak, > 6 mm calsium 
caseinate agar; range from 11.0 to 21.6 mm, mean, 17.4 mm) in all 10 dogs with SEPI when 
tested with radial enzyme diffusion (RED). The result using X-ray films was analogous with 
the RED assay (positive) in all except 1 of the 10 dogs. 
 
8.1.3  Serum TST 
 
Figure 3, Study I summarizes the results of the TLI-stimulation tests (TST). Control dogs 
(n=10) showed a significant increase in the mean (±SE) cTLI concentration from 10.3 ± 0.52 
µg/L (range, 7.4 to 12.6 µg/L) to 35 ± 10.96 µg/L (range, 13.0 to 114.8 µg/L) after secretin 
and cholecystokinin stimulation. No significant increase in cTLI levels occurred in dogs with 
clinical EPI (n=6). In these dogs mean (±SE) fasting cTLI concentrations were 1.0 ± 0.24 
µg/L (range, 0.3 to 1.9 µg/L) before and 1.2 ± 0.28 µg/L (range, 0.4 to 2.3 µg/L) respectively 
after stimulation. The 12 dogs with confirmed SEPI showed a significant response to TST. In 
this group the mean (±SE) fasting cTLI was 2.7 ± 0.28 µg/L (range, 1.0 to 4.1 µg/L) and after 
stimulation 22.2 ± 5.71 µg/L (range, 4.7 to 61.2 µg/L). The extent of response varied from 
dog to dog but in all except 1 dog, the cTLI concentrations increased to > 5.0 µg/L after TST. 
The response to stimulation was significantly higher in both control dogs and dogs with SEPI 
than in dogs with clinical EPI. No difference was observed in TST between dogs with SEPI 
and control dogs. 
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8.2  Morphological findings during progression of PAA  (I, II) 
 
Pancreatic gross pathological, histological and ultrastructural studies were carried out on dogs 
with SEPI and partial PAA. The results were compared to findings seen in dogs with clinical 
EPI due to severe PAA and to those in healthy control dogs. 
 
8.2.1  Gross pathology  (I) 
 
In control dogs, normal pancreas was found. In dogs with SEPI, gross examination showed 
partial atrophy of the pancreas; the pancreatic mass was diminished and although the pancreas 
was normal in length it was thinner than a normal one. Within the normal tissue, there were 
scattered areas that had lost their glandular appearance. These changes were similar in all 
dogs but varied in extent. No signs of firm, nodular, or haemorrhagic tissue were observed 
(Fig.2, Study I). In dogs with clinical EPI, findings typical for severe acinar atrophy were 
found. The pancreas was thin, transparent and had lost its normal glandular tissue.  
 
8.2.2  Histopathology  (II) 
 
Control dogs 
 
In the control dogs, histologically normal exocrine and endocrine pancreas was found. Signs 
of inflammation were absent, except for a few individual lymphocytes within the ductal 
epithelium. Occasionally, in all five control dogs, isolated scattered apoptotic bodies were 
detected within the acinar cells. The judgment of apoptosis was based on the identification of 
membrane-bound apoptotic bodies, large enough to be recognized under a light microscope.  
 
Subclinical phase 
 
In 12 dogs of 13 with SEPI, the pancreatic sections revealed a histologically normal, partially 
affected and severely atrophied acinar structures. In one dog, the section contained only 
histologically normal acinar architecture. The main finding in dogs with SEPI was a marked 
lymphoid cell inflammatory reaction that was most extensive in the border zone area, where a 
gradual loss of normal acinar architecture was observed. These areas were defined as active 
border zones. The inflammatory cells had infiltrated from the active border zone into normal 
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acinar tissue. Numerous intra-acinar lymphocytes were detected in both histologically normal 
acini and partly affected acini (Fig. 1 and 2, Study II). Occasionally, several separate active 
border zone areas were found within the same lobules, giving the appearance of piecemeal 
tissue destruction. In addition, single lymphocytes or foci of lymphocytes were detected in 
otherwise histologically normal lobules. The predominating inflammatory cells were small 
and medium-sized lymphocytes. Besides lymphocytes, plasma cells and macrophages were 
also found. Plasma cells were seen more frequently in the areas of more advanced tissue 
destruction. In four dogs, eosinophils were detected in the border zone area. In two dogs, focal 
mononuclear cell infiltration resembling lymphoid follicles were detected. The inflammatory 
reaction in the border zone in dogs with SEPI was not associated with any increase in the 
amount of fibrous connective tissue.  
 
From the border zone areas towards the atrophied parenchyma, the inflammatory reaction 
became milder. In the atrophied parenchyma, the degree of inflammatory reaction varied, 
usually consisting of multifocal lymphocytes scattered among atrophied tissue. More 
extensive focal infiltrates were sometimes found. Intraepithelial lymphocytes were frequently 
found in the ductal epithelium. In two dogs, the sections included both active and inactive 
border zones. In the inactive border zone, there was a sharp demarcation line between normal 
and atrophied tissue, and no gradual destruction of the acini was found (Fig. 3, Study II). 
 
Gradual loss of normal acinar architecture was always associated with inflammation. 
Subsequent to the loss of acinar cells, the remaining parenchyma was composed of 
disorganized cells and inflammatory cells. As tissue destruction continued, the ductal 
structures became more prominent. In atrophied tissue, there was a slight increase in both 
intralobular and periductal fibrosis. 
 
In nine dogs with SEPI, apoptotic bodies were found in the cytoplasms of individual acinar 
cells, usually in otherwise histologically intact acini (Fig. 2, Study II). In some dogs, an 
increased number of apoptotic bodies were detected near the active border zone area, but 
usually no defined pattern was found. 
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Clinical phase 
 
In 6 of 10 dogs with clinical EPI, the exocrine pancreatic tissue had become totally atrophied. 
In 4 dogs, isolated areas with intact acinar structure were also found. These areas were 
separated from atrophied parenchyma by a sharp demarcation line such as an inactive border 
zone. The inflammatory reaction in the atrophied parenchyma varied and was usually less 
prominent than in subclinical phase. The atrophic tissue consisted of disorganized cells, ductal 
structures and adipose tissue. Typically, in advanced cases, the ducts were clearly visible and 
varied from small cuboidal epithelium lined ducts to large dilated ones with columnar 
epithelium. Fibrosis was usually slightly increased in the clinical phase compared to the 
subclinical phase. However, tissue replacement by fat was more prominent than fibrosis (Fig. 
4, Study II). 
 
8.2.3 Ultrastructure  (II) 
 
Control dogs 
 
The sections of the control dogs were shown to have normal acinar structure and usually 
cytological details of normal appearance  (Fig. 8, Study II). In some acinar cells mitochondria 
had lamellar densities and inclusions. Inflammatory cells were rare or not present. 
Occasionally, single apoptotic bodies were identified within acinar cells.  
 
Subclinical phase 
 
In dogs with SEPI, the exocrine parenchyma was typically affected by a moderate to severe 
mononuclear cell inflammatory reaction. Characteristically, numerous lymphocytes were 
found infiltrating within the acinar basement membrane. These intra-acinar lymphocytes were 
found both in acini that revealed no other ultrastructural changes and in partially affected 
acini (Fig. 9, Study II). A few scattered lymphocytes were found within the ductal epithelium. 
Occasionally, macrophages were also seen within the acini and in the ductal epithelium. 
 
 
 
 
 46 
 
In one dog with SEPI, the section contained no remaining acinar cells and the findings were 
similar to those of dogs in the clinical phase. In general, the pancreas sections of dogs with 
SEPI included both unaffected acini and acini showing various stages of degeneration. The 
acinar architecture was still identifiable in most of the sections. Slightly affected acinar cells 
had a mildly dilated RER and normal or mildly swollen mitochondria. The nuclei were 
unaffected and the zymogen granules were similar to those in normal acinar cells. Moderately 
affected cells showed increased RER dilatation and disorganization, and the homogeneous 
swelling of mitochondria. Numerous zymogen granules were still present. In the severely 
affected, necrotic cells, the RER was markedly dilated and vesiculated, the nuclei were 
pyknotic and cell sizes had decreased. The zymogen granules were less abundant, but normal 
in size and shape, and no fusion of granules was found (Fig. 10, Study II). Prozymogen 
granules, larger and less electron dense than zymogen granules, were found in some acini. In 
these acini, the lumen was usually dilated and filled with secretory material. 
 
In addition to the gradual degenerative changes described, sometimes markedly changed 
mitochondria were observed in acinar cells, which showed no visible alterations in RER. 
These changed mitochondria showed lamellar densities and inclusions, similar to those of the 
control dogs. Occasionally, in otherwise normal or mildly affected acini, large autophagic 
vacuoles were found containing cell debris and unidentified material.  
 
In some dogs with SEPI, apoptotic bodies were identified within the acinar cells. Typically, 
more than one apoptotic body was found, either in normal or affected acini. In some acini, 
both apoptotic bodies and intra-acinar lymphocytes were found (Fig. 9, Study II). 
 
As the surrounding acinar cells were being gradually destroyed, the centroacinar cells and 
other ductal cells were becoming more prominent. Morphologically the centroacinar cells and 
ductal cells lining the intercalated ducts were comparable to those of the control dogs. The flat 
ductal cells had typically large, electron lucent granules in the cytoplasm (Fig.11, Study II). 
Occasionally in the partially destroyed parenchyma, duct-like structures were found, which 
comprised altered acinar cells and cells resembling ductular cells lining a dilated empty 
lumen. Acinar cells had decreased in height and had markedly dilated RER and swollen 
mitochondria. Zymogen granules of normal size and electron density were present, although 
decreased in number. The ductular cells mostly resembled centroacinar cells and flat ductular 
cells (Fig. 12, Study II). 
 47 
 
In more the advanced stages of destruction, the acinar cells were rarely or if ever seen and the 
parenchyma consisted of ducts varying extensively in size and shape. The lumens of these 
ducts were usually markedly dilated. Small ducts were lined by a flat cuboidal epithelium and 
when the sizes of the ducts increased the epithelium gradually changed from cuboidal to 
columnar. There were numerous small electron dense granules in the apex of the columnar 
epithelial cells. Mitotic activity was not found in any of the ductal cells. The pancreatic islet 
cells became more prominent when the acinar parenchyma had been destroyed. 
 
Clinical phase 
 
In the pancreas sections from dogs with clinical EPI and in one dog with SEPI, no remaining 
acinar cells were detected. The sections showed an altered parenchyma in which ducts 
varying greatly in size, islet cells, fibroblasts, fibrocytes and increased adipose tissue were all 
identified. The inflammatory reaction was usually less severe than found in dogs with SEPI. 
Besides lymphocytes and macrophages, an increased number of plasma cells were found in 
the altered parenchyma. The islet cells were typically scattered among the ductal structures. 
Occasionally, the islet cells were found within the ductal epithelium, but usually not in a 
direct contact with the ductal lumen.  
 
8.3. The role of cellular immune response in the pathogenesis 
of PAA (II, III) 
 
The role of cellular immunity was studied by immunophenotyping the inflammatory cells 
infiltrating the tissue in control dogs, dogs with SEPI/partial PAA and dogs with clinical EPI/ 
end-stage PAA. 
 
Control dogs 
 
In the control dogs, a few or no lymphocytes expressing the CD3, CD4 or CD8 antigen were 
detected and no cells staining positively for the CD79 antigen were found in the pancreas 
sections. Positive staining for the lysozyme antigen was seen in a few granulocytes. 
Macrophages were not present. 
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Subclinical phase 
 
In dogs with SEPI, the majority of the lymphocytes infiltrating the pancreas were CD3+ T-
cells. Characteristically, the lymphocytes infiltrating between normal acini, intra-acini and 
within the ductal epithelium were CD3-positive (Fig. 5, Study II).  
 
Further immunophenotyping of the lymphocytes showed that generally, CD4+ and CD8+ T-
cells were present in almost equal numbers, but the distributions of the lymphocyte subsets 
were different. The CD4+ T-cells usually formed large cellular infiltrates and were 
multifocally distributed in the affected parenchyma. The CD8+ T-cells were more widely 
scattered throughout the parenchyma than the CD4+ cells. In sections where both normal and 
affected acinar parenchyma were present, a predominance of infiltrating CD8+ T-cells was 
found. In particular, lymphocytes infiltrating an otherwise histologically normal parenchyma 
were mainly CD8+ (Fig. 1, Study III).  
 
Also numerous CD79+ cells representing B-lymphocytes and plasma cells were found in 
sections with marked T-cell infiltration. Plasma cells showed diffuse cytoplasmic staining and 
the rest of the CD79+ cells, considered as B-lymphocytes, showed membrane associated 
staining. The CD79+ cells had a tendency to form large cellular infiltrates, but were also 
found scattered within a partially affected parenchyma. In some sections, clusters of 
mononuclear cells resembling lymphoid follicle germinal centres were observed. These 
lymphoid follicles typically showed intense staining with the CD79 antibody. In some 
follicles, also CD4+ cells were found, but CD8+ cells were usually absent (Fig. 2, Study III).  
 
Scattered lysozyme positive macrophages were present in the areas of lymphocytic infiltration 
and advanced destruction of acinar parenchyma. In the normal acinar, no parenchyma 
infiltrating macrophages were detected.  
 
The Langerhans islet β-cells, which stained positively for insulin, were located in large groups 
among exocrine parenchyma in dogs with SEPI (Fig. 6, Study II). In the more severely 
atrophied parenchyma, the insulin-positive cells formed small irregular groups scattered 
among the ductal structures (Fig. 7, Study II). 
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Clinical phase 
 
In dogs with clinical EPI and in the atrophied tissue of dogs with SEPI, the lymphocytic 
inflammatory reaction was usually mild to moderate. Most of the scattered lymphocytes were 
CD3- positive, and both CD4+ and  CD8+ T-cells were detected. Only a few or no CD79+ B-
lymphocytes or plasma cells were found. Some macrophages were present in the atrophied 
parenchyma.   
 
8.4  The role of humoral immune response in the pathogenesis of PAA  (III) 
 
8.4.1  Serum protein electrophoresis and immunoglobulin levels    
 
Serum protein electrophoresis revealed no monoclonal components in any of the serum 
samples tested. A tendency towards an increase in the γ-globulin fraction was detected in dogs 
with SEPI (6.8 ± 0.7 g/L; mean, ±SE) and clinical EPI (7.0 ± 0.7 g/L) when compared to the 
control dogs (5.1 ± 0.3 g/L; p = 0.0557). The α-1 globulin fraction was significantly (p = 
0.0075) decreased in dogs with clinical EPI (5.4 ± 0.6 g/L) when compared to the control 
dogs (7.6 ± 0.2 g/L) and dogs with SEPI (8.0 ± 0.8 g/L).  
 
Serum immunoglobulins were quantified by radial immunodiffusion. No significant 
differences were found in IgG, IgM or IgA concentrations when comparing control dogs, dogs 
with SEPI and dogs with clinical EPI (p > 0.05).  
 
8.4.2  Serum autoantibodies 
 
The indirect immunofluorescence method was employed to detect any serum autoantibodies 
against pancreatic tissue components. A weak positive staining reaction against a granular 
component of the acinar cell cytoplasm was found with a serum dilution 1:2 in 5/9 dogs with 
SEPI and in 3/10 dogs with clinical EPI, but not in the control dogs (Fig. 3, Study III). No 
reactions against the ductal epithelial cells were detected. 
 
In an attempt to try identify a possible autoantigen, immunoblotting analysis was performed 
using dog sera and both non-reduced and reduced pancreatic homogenates as target antigen 
mixtures. No apparent differences between sera from the control dogs, dogs with SEPI or 
clinical EPI in the protein band patterns that stained positively were observed with either non-
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reduced and reduced pancreatic homogenates. With both types of homogenates, interpretation 
of the results was affected by a blurring of the protein bands and strong background staining 
especially in the > 45-55 kD areas. 
 
Positive results in serum antinuclear antibody testing were found in 3/13 of the control dogs, 
3/9 of dogs with SEPI and 1/10 dogs with clinical EPI (at serum titres 1:20). A speckled 
immunostaining pattern was most commonly detected. Indirect immunofluorescence staining 
was used for the analysis of antibodies against liver, kidney, gastric mucosa, oesophagus, 
adrenal glands and salivary glands, but no differences was found between control dogs, dogs 
with SEPI and dogs with clinical EPI. 
 
8.5  Response to long-term enzyme replacement treatment (IV)  
 
Questionnaires were returned by 110 (76%) owners of dogs with EPI and 156 (74%) owners 
of control dogs. Of dogs with EPI, 80 were alive and 30 were dead at the time of the study.  
For statistical analysis, data were used from 145 healthy control dogs (72 German shepherd 
dogs and 73 rough-coated Collies), and 76 dogs with EPI (45 German shepherd dogs and 31 
rough-coated Collies)(Table 1, Page 39.). The study included information of EPI-group dogs 
which were alive and fed (at the time of the survey) a nonenteric-coated enzyme supplement 
(powdered supplement, Viokase V, Fort Dodge Laboratories, Iowa, or raw chopped 
pancreas). Four dogs with EPI which were fed a different enzyme supplement were excluded 
from the study. The enzyme supplementation had lasted from 4 months to 1 year in 20% of 
EPI-group dogs, 1 to 2 years in 22%, 2 to 4 years in 45%, and more than 4 years in 13% of 
EPI-group dogs. Powdered enzymes were given to 40 dogs and raw chopped pancreas to 36 
dogs. The use of enzyme supplements was similar between the two breeds.  
 
A comparison of the relative frequency distributions of gastrointestinal signs between EPI- 
and control-group dogs revealed significant differences in all signs (p < 0.05) (Table 1, Study 
IV). The prevalences of the 11 gastrointestinal signs, classified as typical signs of EPI, were 
more common in EPI-group dogs, compared with control-group dogs (Table 3, Page 51.). No 
significant difference was found between dogs receiving powdered enzymes or raw chopped 
pancreas, nor when EPI-group dogs were compared on the basis of how long treatment had 
lasted. The difference between breed was significant for only in a few signs, such as 
coprophagia (Table 2, Study IV).   
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Table 3. Prevalences of typical signs in dogs with EPI during enzyme replacement 
treatment, compared with clinically normal dogs. 
Clinical signs % of dogs  
with EPI 
n = 76 
% of control 
dogs 
n = 145 
Yellow faeces 51 3 
Increased faecal volume 40 12 
Pulpy faeces 33 2 
Coprophagia, sometimes 30 12 
Indoor defecation, sometimes 25 11 
Flatulence, often 29 1 
Defecation frequency, > 3 times/day 23 4 
Thinness 21 4 
Ravenous appetite 21 4 
Diarrhoea, ≥ 1 to 2 times/week 17 2 
Borborygmus, often 12 1 
Significant (p< 0.05) difference in all signs between EPI- and control dogs 
 
The general response to treatment was estimated according to the number of typical signs of 
EPI in each dog. An excellent or good response was found in 47% of the EPI-group dogs. 
These dogs had no more than 2 of 11 typical clinical signs of EPI and they did as well as most 
(97%) of the control-group dogs. In 33% of dogs, a satisfactory response was found with 3 to 
5 typical clinical signs. Poor response to treatment was found in 20% of EPI-group dogs that 
had 6 or more typical signs of EPI (Table 3, Study IV).  The owners were asked to assess their 
dog’s response to treatment by comparing the dog’s current health with that before the first 
signs of EPI. Of the owners, 50% estimated that their dog’s current health was similar, and 
33% thought that at the time of the study their dogs were healthier.  
 
In dogs receiving raw chopped pancreas, the pig pancreas was most commonly used (72%), 
followed by cattle (19%), and lamb or reindeer (9%). The amount of the raw pancreas offered 
was 87 ± 44 g/meal (mean, ±SD). The amount of powdered enzyme (Viokase V) given per 
meal was 3.0 ± 1.5 g. The initial amount of enzyme supplementation was increased in 11% of 
dogs with powdered enzyme and in 12% of dogs with raw pancreas. In 18% of the dogs on 
long-term treatment, the amount of powdered enzyme was decreased. The mean (±) estimated 
monthly costs were $38 ± $21 for powdered enzyme and $11 ± $8 for raw pancreas.  
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Problems were reported by two thirds of the owners feeding raw pancreas (eg, 
impracticability in everyday use and difficulties in availability) and by half of the owners 
feeding powdered enzyme (eg, cost, supply difficulties). During long-term treatment, the type 
of enzyme supplementation was changed in 32% of the dogs for various reasons (eg, the high 
price of the previous supplements, practical difficulties, persistent clinical signs).   
 
When the enzyme treatment was started, dietary modifications were made in 80% of the dogs 
with EPI. In general, dietary modifications were made by changing the previous regular dry 
dog food to some other type of dry dog food (45%), or by starting to feed the dogs a 
homemade diet (28%). A special commercial diet was fed to 22% of the dogs. At the time of 
the study, EPI- and control-group dogs were fed various brands of regular dog food and 
various homemade diets. In general, the most commonly fed dry foods were similar in both 
groups. Homemade diets consisted mainly of rice, potato, meat, chicken and cottage cheese. 
Two dogs with EPI were fed a special diet continuously. Most EPI- and control group dogs 
had some variation in their daily dietary routines. Any sudden dietary changes resulted in 
unwanted clinical signs significantly more often in the EPI-group dogs (82%) than in the 
control group dogs (45%). Adverse reactions to various diets and dietary ingredients were 
seen significantly more often in the EPI-group dogs (77%), than in the control dogs (55%). 
Clinical signs, as reported by the owners, due to dietary intolerance were diarrhoea, 
flatulence, borborygmus and dermatological signs.   
 
Besides enzyme supplements, other medications to treat gastrointestinal tract signs were used 
in 62% of EPI-group dogs. Of adjuctive treatments, antibiotics were used in 42% of the dogs 
during initial treatment and in 45% during long-term treatment. Tylosin was the most 
commonly used antibiotic. The most common indications for antibiotics were diarrhoea, 
flatulence and borborygmus. During long-term treatment the antibiotics were not usually used 
for more than a week and the course was repeated once or twice a year. Two dogs received 
tylosin daily. Of the other adjunctive medications, H2-antagonist, cimetidine, was used in 
three dogs and in one of them continuously. Cobalamin, was administered parenterally to 41% 
of the dogs, usually once or twice during treatment, to improve general health and the coat. 
 
Dermatological signs were found increasingly in the EPI-group dogs (46%) compared to the 
control-group (24%). The most common problem was excessive hair loss and exemia. The 
dermatological problems were more commonly found in the German shepherd dogs.  
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Besides data from 76 dogs with EPI alive at the time of study, data was analyzed from 30 
dogs with EPI that were deceased before the study was initiated. Of these dogs, 2 had died 
naturally, 20 were euthanized during the first year after diagnosis (one of the dogs 
immediately after diagnosis was confirmed), and 8 were euthanized later. The most common 
reason for euthanasia was the persistence of clinical signs, which was the only reason for 
euthanasia in 13 dogs and one of the reasons in 7 dogs. The most common persistent signs 
were diarrhoea and weight loss.      
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9.  DISCUSSION 
 
9.1  Diagnosis of partial PAA  
 
PAA is characterized by the progressive destruction of pancreatic acinar tissue, leading to 
inadequate secretion of pancreatic digestive enzymes and to the clinical maldigestion signs of 
EPI. Although PAA is a well-recognized disease, previous studies have failed to show the 
etiopathogenesis of the disease (Thordal-Christensen and Coffin 1956, Geyer et al 1968, 
Holroyd 1968, Freudiger 1971, Hill et al 1971, Säteri 1975, Hashimoto et al 1979, Rimaila-
Pärnänen and Westermarck 1982). Diagnosis of exocrine pancreatic dysfunction in dogs has 
been largely based on the typical clinical signs of EPI. Nevertheless, when clinical signs of 
EPI appear in dogs with PAA, the atrophy of acinar tissue is already almost total, offering 
little in terms of pathogenesis. To study further the etiopathogenesis of PAA, the diagnosis 
should be set in an earlier phase, when the tissue destruction is still in progress.  
 
Study I assessed whether the specific tests used for the evaluation of pancreatic function in 
dogs are valuable for diagnosing exocrine pancreatic dysfunction already in the subclinical 
phase, and whether these tests could be used as a diagnostic aid for the early detection of 
PAA. 
 
In human medicine, exocrine pancreatic dysfunction can be diagnosed and staged to mild, 
moderate and severe forms by using a direct pancreatic function tests, such as secretin-
cholecystokinin test. In this test the pancreatic juice is aspirated directly from the duodenum 
to analyze the volume, and bicarbonate and enzyme content (Lankisch 1993). In dogs, the 
direct tests are not a practical alternative for screening pancreatic dysfunction, as they are 
laborious, and have to be carried out in anaestesia, which may have a negative effect on 
pancreatic secretion (Tiscornia et al 1972, Säteri 1975, Boden et al 1977). Thus in dogs, 
indirect pancreatic function tests, such as serum cTLI, serum BT-PABA, faecal proteolytic 
activity and faecal elastase measurements are used for diagnosing EPI (Hill and Kidder 1970, 
Westermarck and Sandholm 1980, Batt and Mann 1981, Williams and Batt 1988, Spillmann 
et al 2001a).   
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Serum cTLI measurement has been widely used as a screening test for canine exocrine 
pancreatic dysfunction, as it has been shown to be both a sensitive and practical method for 
detecting severe EPI. Abnormally low serum cTLI values (< 2.5 µg/L, normal range > 5.0 – 
35.0 µg/L) have been shown to indicate severe loss of pancreatic function and are found in 
dogs with clinical signs of EPI due to end-stage PAA (Williams and Batt 1988, Westermarck 
et al 1993a). 
 
There are reports indicating that the cTLI measurement may be used in the early diagnosis of 
exocrine pancreatic dysfunction. It has been reported that occasionally serum cTLI values can 
be found in subnormal range of 2.5 - 5.0 µg/L (Williams and Batt 1988). Subnormal cTLI 
values may be considered suggestive for impaired pancreatic function. However, to date, no 
comprehensive studies have been published on the clinical significance of these values. It has 
also been shown that serum TLI concentration reflect both the secretory capacity and 
functional mass of the exocrine pancreas (Andriulli et al 1981, Simpson et al 1992), and that 
low serum values may precede the appearance of clinical signs of EPI in dogs with PAA 
(Westermarck et al 1993a, Boari et al 1994).  
 
In Study I, the screening of the clinical histories of dogs with a single low serum cTLI (< 5.0 
µg/L) revealed a number of dogs in which subnormal pancreatic function could be suspected. 
Dogs with a subnormal range cTLI (2.5 - 5.0 µg/L) were found rather frequently (6% of all 
serum samples measured for cTLI). Clinically, these dogs varied from apparently healthy 
dogs to those with various gastrointestinal signs. Subnormal pancreatic function was also 
suspected in those exceptional dogs with an abnormal low serum cTLI (< 2.5 µg/L) indicating 
severe pancreatic dysfunction but without any clinical evidence of EPI.  
 
To study whether a low cTLI level in these dogs was an occasional finding or an indicator of 
pancreatic dysfunction, repeated cTLI measurements were performed (Study I). Interestingly, 
in retesting, in half of the dogs cTLI was repeatedly < 5.0 µg/L but the dogs still showed no 
signs of EPI, thus suggesting subnormal pancreatic function in these dogs. The suspected 
pancreatic disease was verified by laparotomy and pancreatic biopsy, showing partial PAA in 
all 12 dogs studied. The dogs were all either German shepherd dogs or rough-coated Collies. 
Both breeds are known to be predisposed to PAA (Weber and Freudiger 1977, Westermarck 
1980, Westermarck et al 1989). When the pancreas still has enough reserve secretory 
capacity, dogs with partial PAA showed no clinical signs of exocrine pancreatic dysfunction. 
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Based on the results, it was concluded that repeatedly low serum cTLI values (< 5.0 µg/L) in 
a clinically healthy dog are a valuable marker of subclinical EPI and highly suggestive for 
partial PAA in German shepherd dogs and rough-coated Collies. 
 
However, Study I showed also that using serum cTLI measurement to diagnose subclinical 
EPI has some limitations, since in some dogs a low serum cTLI was only an occasional 
finding. These dogs also included breeds other than German shepherd dogs and rough-coated 
Collies. In the absence of further examinations, i.e. laparotomy, it remained uncertain whether 
these dogs had a pancreatic disease or not. Therefore, repeated measurements are needed to 
increase diagnosis accuracy, especially when a single subnormal cTLI (2.5 - 5.0 µg/L) value 
is detected. It has been observed in human patients that overlapping TLI results can occur in 
patients with mild to moderate exocrine pancreatic dysfunction and those with normal 
pancreas (Andrian 1980, Gullo et al 1980, Ruddell et al 1981). In a progressive disease such 
as PAA in dogs, cTLI concentrations can be expected to vary from subnormal to normal 
depending of the degree pancreatic tissue loss. Further, a serum cTLI value within a normal 
range does not necessary exclude the possibility of milder forms of acinar atrophy, especially 
in breeds predisposed to PAA. 
 
The diagnostic value of other indirect pancreatic function tests: BT-PABA test and faecal 
proteolytic activity after soybean stimulation (Westermarck and Sandholm 1980, Batt and 
Mann 1981,) to diagnose subclinical EPI was assessed in Study I. The results showed that 
serum BT-PABA and SST were insufficiently sensitive to detect SEPI, although they are both 
good indicators of clinical EPI (Westermarck and Sandholm 1980, Batt and Mann 1981, 
Williams and Batt 1986, Westermarck et al 1993a). The BT-PABA test may support the 
diagnosis of SEPI but is not specific for pancreatic disease and abnormal results have been 
found also in small intestinal disease (Batt and Mann 1981, Williams and Batt 1986).  The 
BT-PABA test was performed on only a few dogs. Compared to the other tests, the BT-PABA 
test is both impractical and expensive. SST is a semiquantative test and its value for staging 
the level of dysfunction was limited. This was expected because dogs with SEPI have 
remaining pancreatic reserve secretory capacity and pancreatic stimulation with soybean will 
lead to results within the normal range. A comparison of the results of the BT-PABA test and 
SST with those of cTLI measurements showed that serum cTLI is more valuable in the early 
diagnosis of exocrine pancreatic dysfunction. Williams and Batt (1986) reported similar 
findings. 
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A new indirect pancreatic function test, canine faecal pancreatic elastase, has been shown to 
be valuable to confirm the diagnosis of severe clinical EPI (Spillmann et al 2001a). A recent 
study of the diagnostic value of the faecal elastase test to diagnose subclinical disease showed 
that although significantly lower faecal elastase values were detected in dogs with SEPI than 
in the control dogs, the overall practical value of the test for diagnosing and screening for 
subclinical EPI was found to be questionable (Wiberg et al 2001). This is because of the 
overlapping results in the SEPI and control dogs and because of remarkable day-to-day 
variations in faecal elastase. It may thus be concluded that, at the moment, serum cTLI 
measurement appears to be the most promising indirect test for the early diagnosis of exocrine 
pancreatic dysfunction. 
 
In this study, the suspected pancreatic disease was verified by pancreatic morphological 
examination during laparotomy (Study I and II). Previous studies have shown that pancreatic 
biopsies can be taken without further complications by laparotomy dissecting a small 
pancreatic sample, or by laparoscopy using crushing forceps (Westermarck et al 1993a, Twedt 
1999, Spillmann et al 2000, Harmoinen et al 2002). Also, in this study no complications were 
detected after taken the biopsies.  Laparotomies in dogs with subclinical disease revealed in 
all dogs already grossly recognizable pancreatic changes, which varied with severity. Gross 
findings were similar, but not as severe as in end-stage PAA, showing scattered areas of 
atrophied tissue among normal glandular tissue.  In dogs with partial PAA, the remaining 
secretory capacity of the pancreas depends on the degree of atrophy. However, because of the 
uneven distribution of atrophic changes, it was difficult to estimate the remaining normal 
pancreatic mass. Therefore, no correlation analyses between morphological changes and 
serum cTLI concentrations or the other pancreatic function tests were attempted (Study I). 
 
To further assess the reserve secretory capacity of the remaining exocrine pancreatic tissue, it 
has been thought that the exogenous stimulation of the pancreas with enterohormones secretin 
and cholecystokinin may lead to different TLI stimulation reactions depending on the degree 
of pancreatic dysfunction (Spillmann 1995). In Study I, both secretin and cholecystokinin 
were used for maximal pancreatic stimulation. Secretin stimulates the secretion of pancreatic 
bicarbonate-rich fluid, which increases pressure in the pancreatic ducts and allows enzymes to 
leak into the bloodstream. On the other hand, cholecystokinin acts as a direct stimulant of 
enzyme secretion. Previously, TLI has been measured in humans, dogs and cats after various 
stimulation methods (Adrian 1980, Bonora et al 1980, Vezzadini et 1980, Spillmann 1995; 
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Spillmann et al 2000). Study I demonstrated that dogs with end-stage PAA and clinical EPI 
showed no response to enterohormonal stimulation in contrast to dogs with partial PAA and 
SEPI. This indicates that in the subclinical phase there is still some reserve secretory capacity 
in the pancreas despite the fact that some dogs with SEPI had low fasting values typical for 
clinical disease. However, the cTLI stimulation test was not found to be more valuable in 
diagnosing SEPI than repeated cTLI measurements. This is because the degrees of stimulation 
responses in dogs with SEPI and in the normal control dogs were similar, despite different 
fasting cTLI concentrations. Although in the subclinical phase, low fasting serum cTLI 
concentrations were usually increased to normal level after stimulation, this response was not 
seen in all dogs and the level of responses varied from dog to dog. The value of the TST in 
staging the level of dysfunction remained uncertain, as it was not possible to correlate the 
results of this test with the amount of remaining pancreatic tissue. 
 
Study I showed that, based on the clinical findings and serum cTLI measurement, it is 
possible to diagnose EPI in the subclinical and clinical phase and in breeds predisposed to 
PAA, these findings are suggestive for partial PAA and end-stage PAA, respectively. 
Repeatedly low serum cTLI  (< 5.0 µg/L) measurements in dogs showing no clinical signs of 
EPI were found to be a sensitive method for the detection of subclinical disease. However, 
cTLI is probably not useful for diagnosing mild dysfunction or for further staging the level of 
EPI. These limitations should be taken into consideration if cTLI measurement is planned to 
be used as a screening test for subclinical cases, e.g in breeding programmes. The future will 
show the value of the diagnostic criterium given by this study. It will also been seen whether 
similar findings are detected in breeds other than German shepherd dogs and rough-coated 
Collies. 
 
9.2.  Morphological findings during the progression of PAA  
 
The ability to diagnose PAA before the development of total acinar atrophy in the subclinical 
phase offered new possibilities to study the etiopathogenesis of the disease. Previously, it has 
been able to follow the progression of PAA only in a single dog born from the test-mating of 
parents with PAA (Westermarck et al 1993a). Based on the findings of Study I, it was now for 
the first time possible to study the histological and ultrastructural findings in a larger number 
of dogs with partial PAA whilst tissue destruction was still in progress. 
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The main histological feature in the subclinical phase of PAA was a marked infiltration of 
lymphocytes into the exocrine pancreas in distinct contrast to the usually mild inflammatory 
reaction in the clinical phase (Study II). The inflammatory reaction affected only the exocrine 
pancreas and, in the absence of fibrosis, showed a distinct difference in the morphological 
changes in canine chronic pancreatitis (Thordal-Christensen and Coffin 1956, Geyer et al 
1968, Rimaila-Pärnänen and Westermarck 1982, Hänichen and Minkus 1990). Lymphocytic 
inflammation was most extensive in the border zone areas of normal and partially affected 
tissue and lymphocytes had spread into the normal acinar parenchyma. Typical findings 
included numerous intra-acinar lymphocytes, piecemeal appearance of tissue destruction and 
the presence of large groups of lymphocytes resembling lymphoid follicle germinal centres. 
The gradual destruction of acinar tissue was associated with inflammation. In areas of more 
advanced tissue destruction, the findings were similar to those found in end-stage PAA, where 
acinar structure is replaced by atypical parenchyma, ductular structures, and adipose tissue. 
Based on the findings in Study II, the progression of acinar atrophy was divided into 
lymphocytic pancreatitis with active destruction of the acinar structures and end-stage PAA. 
Thus, the term “atrophic lymphocytic pancreatitis” is preferred to describe the pathological 
findings. 
 
Morphological findings during the progression of acinar atrophy indicated the autoimmune 
nature of the disease. Lymphocyte infiltration into the target organ where tissue destruction is 
in progress has been taken as primary evidence for autoimmune reaction (Carnaud and Bach 
1993, Rose and Bona 1993). Findings in the subclinical phase of PAA were similar as 
reported for autoimmune diseases such as Hashimoto’s thyroiditis in humans and lymphocytic 
thyroiditis both in humans and in dogs (Beierwaltes and Nishiyama 1968, Fritz et al 1970, 
Gosselin et al 1981, Gosselin et al 1982, Lucke et al 1983, Conaway et al 1985, Beale 1991). 
Characteristics for autoimmune diseases is also that the susceptibility to disease is 
multifactorial, including both genetic and environmental factors (Rose and Bona 1993, 
Janeway et al 1999). PAA has been reported to be inherited in German shepherd dogs and 
rough-coated Collies (Weber and Freudiger 1977, Westermarck 1980, Westermarck et al 
1989, Moeller et al 2002), thus supporting the hypothesis of an autoimmune disease. All the 
dogs diagnosed with partial PAA were either German shepherd dogs or rough-coated Collies. 
Some of these dogs were known to have full siblings with the clinical disease (Study I and II). 
To date, the studies have failed to identify any common environmental factor predisposing to 
PAA (Räihä and Westermarck 1989). The ability to diagnose the disease before severe 
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atrophy may now offer further possibilities to study and identify the possible factors involved 
in triggering the progression of atrophy. 
 
Previously, only scant attention was given to the possibility of PAA being an autoimmune 
disease. One reason for this was that although some inflammatory reaction can be found in the 
severely atrophied tissue, the significance of the inflammation remained unclear because of 
the end-stage phase of the process (Freudiger 1971, Säteri 1975, Rimaila-Pärnänen and 
Westermarck 1982). There has been general consensus that the atrophy process is 
degenerative (Hill et al 1971, Säteri 1975, Hashimoto et al 1979, Rimaila-Pärnänen and 
Westermarck 1982). The degenerative nature was further supported by a study that followed 
the progression of acinar atrophy in a single dog (Westermarck et al 1993a). Westermarck et 
al (1993a) reported that the degenerative changes in acinar cells were, in the absence of 
marked inflammatory reaction, the most distinctive findings. In Study II, morphological 
changes in the pancreas were studied in a larger number of dogs. The severity of the 
morphological pancreatic changes was found to greatly depend on the site of the biopsy. 
Thus, failure to demonstrate inflammation by biopsy may be a result of the uneven 
distribution of the inflammatory changes in an affected pancreas. 
 
Interpreting the histological findings in the subclinical phase of acinar atrophy raises the 
question of whether the inflammatory reaction is the initial abnormality or only secondary to 
pre-existing changes in the ultrastructure (Westermarck et al 1993a) or whether it is a result of 
functional abnormalities of the acinar cells. However, ultrastructural findings in Study II 
suggested that inflammatory reaction had an important role in the tissue destruction. 
Numerous intra-acinar lymphocytes were detected not only in partially affected acini, but also 
in unaffected acini, which revealed no other obvious ultrastructural changes.  
 
In the pancreatic sections of dogs with partial PAA degenerative changes were also found 
(Study II). The degenerative changes of acinar cells observed were similar to those described 
previously by Westermarck et al (1993a) in one dog. These were characterized by a dilatation 
of RER, a swelling of mitochondria, and nuclear changes, which resulted in cell necrosis. 
However, these progressive degenerative changes are typically seen in cell swelling, a process 
that can be caused by various insults (Ghadially 1988). As the most obvious alterations in 
acinar cells in dogs with partial PAA occurred in association with inflammation, it is possible 
that inflammatory reaction is, at least partly, the cause of these degenerative changes. The 
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importance of the control dogs was obvious when the ultrastructural degenerative changes 
were interpreted. A mild dilatation of RER and mitochondrial swelling or inclusions were also 
occasionally observed in the control dogs. As a sensible organ, the pancreas is susceptible to 
artefactual changes induced by tissue handling (Jubb 1993) and thus some of the degenerative 
and even necrotic changes should be interpreted carefully. Westermarck et al (1993a) 
suggested that degenerative changes of acinar cells and zymogen granule fusion were among 
the first alterations. In Study II, no evidence of fusion or other abnormalities of zymogen 
granules were observed. On the contrary, well-preserved zymogen granules were found even 
in severely affected cells. The larger zymogen granules were considered to be prozymogen 
granules and could be found in both control dogs and dogs with partial PAA, indicating an 
active secretory stage of the normal acini (Tardini et al 1971, Motta et al 1997). 
 
Interestingly, the morphological study (Study II) showed that in the subclinical phase of the 
atrophy process there is both necrotic and apoptotic acinar cell death. It is reported that 
apoptotic cell death may have a significant role in some immune-mediated disease (Patel and 
Gores 1995, Hammond et al 1997), as well as in natural and experimental pancreatic diseases 
(Oates et al 1986, Walker 1987,Walker et al 1993, Iovanna 1996). Recent studies using in situ 
hybridization to detect apoptosis indicate that apoptosis may be found to some extent in end-
stage PAA (Steiner et al 2001). Based on a morphological study, it was difficult to assess the 
significance of apoptotic cell death in tissue destruction in the subclinical phase of PAA 
(Study II). The apoptotic death of acinar cells can occur in the normal pancreas of healthy 
animals and the frequency of apoptotic cell death may be underestimated because apoptosis 
occurs usually in scattered cells (Walker 1987, Patel and Gores 1995, Steiner et al 2001, 
Study II). Therefore, further studies are needed to estimate the role of apoptosis during the 
progress of tissue destruction in PAA. 
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9.3 The role of cellular and humoral immune responses  
        in the pathogenesis of PAA  
 
To study the possible role of cellular immune mechanisms in the pathogenesis of PAA, the 
tissue infiltrating lymphocytes were subjected to immunophenotyping (Study II and III). The 
results of the immunohistochemical study support the hypothesis that cell-mediated 
cytotoxicity plays a major role in the pathogenesis. At the onset of the acinar cell destruction 
in the subclinical phase, the majority of the lymphocytes infiltrating the tissue were T-
lymphocytes and the intra-acinar lymphocytes were all T-cells (Study II). Further 
immunophenotyping of the T-cells showed that, in general, almost equal numbers of the 
CD4+ T-helper cells and CD8+ cells, representing mainly cytotoxic T-cells, were found. 
Typically, cytotoxic T-cells had infiltrated both the affected and normal acinar parenchyma. 
When a gradual destruction of acinar parenchyma was present, the cytotoxic T-cells were 
predominant (Study III).   
 
In general, the findings in Studies II and III are comparable to those reported in cell-mediated 
autoimmune diseases, such as insulin-dependent diabetes mellitus and Hashimoto's 
thyroiditis. These disorders are characterized by a marked T-cell infiltration with a 
predominance of CD8+ cytotoxic cells at the onset of tissue destruction (Bottazzo et al 1985, 
Misaki et al 1985, Itoh et al 1993). However, it has been shown that macrophages and CD4+ 
T-helper cells may have a more significant role in the early phase of cell destruction in the 
cell-mediated diseases (Roep and De Vries 1992, Reddy et al 1995). Macrophages process 
and present antigens to CD4+ helper cells, which in turn are necessary to initiate both cell-
mediated and humoral immune responses (Roep and De Vries 1992, Reddy et al 1995). 
Although the results of Study III suggest a significant role for the infiltrating cytotoxic CD8+ 
cells, it was not possible to assess the role of the different mononuclear cells in the early 
lesions. Macrophages were occasionally present among the infiltrating lymphocytes and in the 
areas of advanced atrophy. However, no infiltrating monocytes/macrophages were detected in 
the normal parenchyma. 
 
In the subclinical phase, the presence of lymphoid follicles and an increased number of B-
lymphocytes and plasma cells suggest that also humoral immune responses are activated 
when the destruction of acinar parenchyma is in progress (Study III). The intensity of the 
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inflammatory reaction was found to decrease on the development of total acinar atrophy. In 
the atrophied pancreas, scattered T-lymphocytes could be detected and only a few B- 
lymphocytes and plasma cells. The likely reason for the results is that any possible immune 
response which may have been present in the earlier phase was no longer active during the 
late clinical phase. 
 
In Study III, the methods for screening the humoral immune status included serum protein 
electrophoresis, quantification of serum Ig-classes or subclasses and the assessment of serum 
autoantibodies. Polyclonal gammopathy, due to activation of the immune response, polyclonal 
B-cell stimulation and an increase in serum IgG and IgM, may be considered to be a typical 
finding in autoimmune diseases. Study III showed an increase in the serum gamma globulin 
fraction in the subclinical and clinical phases of the disease, but no significant changes in 
serum IgG and IgM levels were observed.  
 
The activation of humoral immune responses can be further studied by identifying antibodies 
against certain autoantigens. Many autoimmune diseases have typical patterns of autoantibody 
production (Sinha et al 1990, Janeway et al 1999). Some of the autoantibodies can cause 
clinical manifestations, but in most cases they are used as predictors of the clinical course, to 
diagnose the disease or to assess its severity. Serum autoantibodies can be found in organ-
specific autoimmune diseases despite the fact that they are considered to be mediated mostly 
by cytotoxic T-cells. The role of the autoantibodies in pathogenesis is usually questionable, 
but altogether, they provide further evidence of the autoimmune nature of the disease (Rose 
1989, Sinha et al 1990, Roep and De Vries 1992, Roep 1996, Janeway et al 1999). Study III 
showed that in dogs with subclinical or clinical phase of PAA, serum antibodies directed 
against a coarse granular component of the pancreatic acinar cell cytoplasm were occasionally 
found. Similar antipancreatic antibodies have been reported in human exocrine pancreatic 
diseases (Lendrum and Walker 1975, Lankisch et al 1981, Rumenssen et al 1985). The 
granular immunofluorescence pattern indicated that the autoantibodies could be directed 
against acinar cell zymogen granules.  
 
Although pancreatic-antibodies were not identified in the control dogs, the intensity of the 
positive reaction was so weak that the diagnostic usefulness of the antibodies is questionable 
with current methods (Study III). The antibodies can be a result of the autoimmune reaction, 
but for an unknown reason the reaction could not be detected in all the diseased dogs. On the 
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other hand, the antibodies can develop secondarily to tissue destruction and may thus not be 
pathognomonic to the disease. Because of the patchy nature of the destruction process in the 
pancreas, no effort was made to study the correlation between the immunohistological 
findings and the presence of autoantibodies. 
 
It is possible that the methods used in the Study III were not sensitive enough to detect all 
possible antibodies. In addition to the indirect immunofluoresence test, the immunoblotting 
technique was used as a supportive method. Analysis of the immunoreactive bands failed to 
show any positive correlations to the subclinical or clinical phase of the disease. Analysis of 
the immunoblotting results, however, requires careful consideration as unwanted or non-
specific staining reactions cause problems in interpretation. Immunoblotting has been 
previously used to study antipancreatic antibodies in dogs with clinical EPI, but because of 
the different method and conditions used a comparison of the previous and Study III is 
difficult (Simpson and Cobb 1998). The results of these studies were, however, similar.  
 
The results of the immunological studies suggest that tissue destruction during progression of 
acinar atrophy is largely T-cell mediated, although the presence of numerous B-lymphocytes 
and pancreas-specific antibodies in sera of some dogs indicates that also humoral mechanisms 
are involved. 
 
9.4  Response to long-term enzyme replacement treatment   
 
Once the destruction of acinar tissue has become sufficiently advanced, inadequate production 
of digestive enzymes leads to clinical maldigestion signs of EPI. The primary treatment for 
EPI is to supplement each meal with pancreatic enzymes. Enzyme treatment is, however, 
lifelong and expensive. When EPI is diagnosed, owners are often anxious about the future 
quality of their dog’s life and about the possible problems to be expected during long-term 
treatment. In Study IV, a survey was conducted to find answers to these questions. A 
comparison of the general health status and clinical signs was made between German 
shepherd dogs and rough-coated Collies treated for EPI and apparently healthy dogs of the 
same breeds. In these two breeds the clinical signs of EPI are most commonly due to end-
stage PAA.  
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In general, the response to long-term enzyme replacement treatment was found to be good 
(Study IV). Basically, the treatment regimens were simple and consisted of adding a 
nonenteric-coated enzyme supplement to ordinary dog food. During long-term treatment, a 
marked resolution was achieved for most of the gastrointestinal tract signs typical of EPI, 
although it was not always possible to eliminate all signs. Good resolution was found 
especially for more serious signs, such as continous diarrhoea and malnutrition. The owners’ 
assessments of the response to treatment were surprisingly positive. One reason for this 
finding may be that the clinical signs that often persisted; high faecal volume, yellow and 
pulpy faeces, and flatulence, were considered mild and, as time went on, they were accepted 
as part of normal life. Secondly, the study may lack information on dogs having a poor 
response to treatment, because at least some dogs were already euthanized during early 
treatment. 
 
Despite basically similar treatment regimens, the responses to enzyme supplements in dogs 
with EPI varied considerably. Signs considered typical for EPI were almost completely 
controlled in half of the dogs and their general health was similar to that of clinically normal 
dogs. A poor response to treatment was found in 20% of dogs that had several signs typical 
for EPI. Study IV did not provide answers as to why some of the clinical signs were 
incompletely controlled and why the responses to treatment varied. Further studies are needed 
to investigate the reason for poor responses in individual dogs. Study IV indicated that the 
response to treatment was similar in German shepherd dogs and rough-coated Collies, and 
that the response was not affected by the type of nonenteric-coated enzymes fed, or by the 
length of treatment. 
  
Nonenteric-coated enzyme formulations have been shown to be the most effective 
formulations in the treatment of EPI. The highest enzyme activity in the duodenum is 
achieved by feeding raw chopped pancreas, followed by powdered enzyme extracts 
(Westermarck 1987). In Finland, raw pancreas and powdered enzyme supplements are almost 
exclusively used. Thus, Study IV provided an opportunity to perform a thorough clinical 
comparison of the properties of these two supplements. Feeding raw chopped pancreas and 
powdered enzymes proved to be equally effective in controlling clinical signs. The choice of 
the two preparations was based more on the practical properties, availability and costs of the 
supplements. In some dogs, when the clinical signs were persistent with one supplement, 
changing to the other enzyme extract resulted in improved response to treatment. This 
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observation should be taken into account if the dog does not respond properly to first-choice 
enzyme supplement. In those countries where the use of raw pig’s pancreas is not allowed, 
other animal sources of pancreas, may be used instead. Study IV showed that some of the 
dogs were successfully treated with pancreas from cattle, lamb or reindeer. 
 
It has been reported that after an initial clinical improvement, decreasing the amount of 
enzymes fed did not give rise to a recurrence of the clinical signs (Westermarck et al 1995, 
Williams 2000). No actual effort was made to find the minimum effective dose for most dogs 
included in Study IV. The initial amount of enzyme fed was maintained during long-term 
treatment and was usually 3 g of powdered and 50 g to 100 g of raw chopped pancreas / meal 
for dogs weighing 20 to 35 kg. Although enzyme treatment is usually considered to be 
lifelong, especially in dogs with PAA, it has been shown that dogs initially showing severe 
clinical signs and responding to enzyme supplementation did not need continuous treatment. 
This indicates that, despite atrophy, the pancreas of these exceptional dogs may have some 
reserve secretory capacity remaining (Westermarck and Rimaila-Pärnänen 1989b). In the case 
of poor response to treatment, attempts have been made to increase the amount of enzymes 
fed. However, the value of increasing the dose remains uncertain and is probably of limited 
value (Hall et al 1991, Study IV). 
 
The role of dietary modification in the treatment of EPI has remained questionable. This is 
partly because dietary changes are made when enzyme treatment is started and partly because 
of the great variations among the diets fed. Based on clinical studies, it may be concluded that 
special diets, although they could alleviate some clinical signs, are not usually necessary for 
long-term treatment (Westermarck et al 1990, Hall et al 1991, Westermarck et al 1995). Study 
IV supports this opinion. Dogs treated for EPI can be fed various kinds of ordinary dog food 
if particular attention is paid to individual needs and radical dietary changes are avoided. 
Dogs with EPI appear to be increasingly sensitive to sudden dietary changes and often have 
adverse reactions to various diets.  
 
Of the supportive treatments recommended in the literature, antibiotics are most commonly 
used both in initial and long-term treatment (Hall et al 1991, Williams 2000). Study IV 
showed that during long-term treatment half of the dogs were receiving antibiotics when they 
experienced a recurrence of signs, such as diarrhoea, flatulence and borborygmus. Small 
intestinal bacterial overgrowth may be a problem also during enzyme treatment, thus partly 
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explaining the response to antibiotics in long-term treatment (Williams et al 1987, 
Westermarck et al 1993b). H2- receptor antagonists are not routinely used in the treatment of 
EPI, but were found to be helpful for some dogs with clinical signs despite enzyme treatment 
(Study IV). Cobalamin deficiency is commonly reported in dogs with EPI. Thus, parenteral 
cobalamin injections are recommended when the serum cobalamin levels are low (Batt and 
Morgan 1982, Batt 1990, Hall et al 1991, Williams 2000). During long-term treatment, the 
indications for cobalamin treatment were found to be poor general health or a poor coat 
(Study IV). Dermatological signs were common especially in German shepherd dogs. Thus, 
there may be a need for other additional supportive treatments to control the dermatological 
signs (Study IV). 
 
In conclusion, because the treatment of EPI is lifelong and usually expensive, treatment 
regimens should remain simple, but still pay particular attention to individual needs (Study 
IV). Treatment is started with nonenteric-coated enzyme formulations at the maintenance 
dose and continue feeding the dog its ordinary food. Because of the strong possibility of small 
intestinal bacterial overgrowth antibiotics may be valuable to hasten clinical improvement 
during the initial period of treatment. Parenteral cobalamin is recommended when low serum 
cobalamin values are detected. If the response to initial treatment turns out to be 
unsatisfactory, more aggressive and long-lasting supportive treatments are used. These 
include dietary modifications, antibiotics, and repeated cobalamin treatments. Any co-existing 
small intestinal disease should be diagnosed and treated. Nevertheless, it seems reasonable to 
assume that the response to treatment achieved during the first months will remain fairly 
stable during long-term treatment (Study IV). Even if short relapses of clinical signs may 
develop, permanent deterioration of the clinical condition in dogs with EPI during long-term 
treatment is probably uncommon. Thus, the prognosis for long-term enzyme replacement 
treatment is generally considered to be good.  
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10.   CONCLUSIONS 
 
I  Studies of the early diagnosis and etiopathogenesis of PAA led to the following 
conclusions. 
1. In German shepherd dogs and rough-coated Collies, PAA can be diagnosed in the 
subclinical phase before the total destruction of acinar tissue. Serum cTLI was found 
to be the most valuable diagnostic test for subnormal pancreatic function. Repeatedly 
low serum cTLI values (< 5.0 µg/L) in a clinically healthy dog were shown to be a 
sensitive marker of subclinical EPI and highly suggestive for partial PAA. To increase 
the accurancy of the diagnosis of the subclinical disease, repeated measurements (at 
least two consecutive samples) are needed, especially when a subnormal cTLI value  
(2.5 - 5.0 µg/L) is detected.  
 
2. Histological findings during the progression of PAA were characteristic for an 
autoimmune disease showing marked lymphocytic infiltration into partially atrophied 
acinar parenchyma. The inflammatory reaction was most extensive in the border zone 
areas of normal and affected parenchyma and lymphocytes had infiltrated into 
apparently normal acinar tissue. The gradual destruction of acinar tissue was 
associated with inflammation. In the areas of more advanced tissue destruction, the 
findings were similar to those of end-stage PAA. Term “atrophic lymphocytic 
pancreatitis” was preferred to describe pathological findings. 
 
3. Immunological studies suggested that both cellular and humoral immune responses 
have a role in the pathogenesis of acinar atrophy, although tissue destruction seems to 
be largely mediated by cellular immune mechanisms. Immunohistochemical analysis 
showed that in the subclinical phase, the majority of the infiltrating lymphocytes were 
T-cells, with an almost equal number of CD4+ T-helper and CD8+ cytotoxic T-
lymphocytes. Cytotoxic T-cells were predominant in sections where the gradual 
destruction of acinar parenchyma was present. The occurence of serum autoantibodies 
against pancreatic acinar cells not only suggested activation of the humoral immune 
response but also further indicated the autoimmune nature of the disease.  
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Thus, the etiopathogenetic study suggests that PAA in German shepherd dogs and rough-
coated Collies is a consequence of autoimmune-mediated atrophic lymphocytic pancreatitis. 
Both the previous information about the inheritance of PAA and the current findings of 
marked infiltrative T-lymphocyte inflammation in the gradually atrophying acinar 
parenchyma suggest that the disease is of an autoimmune nature. The major role of cell-
mediated cytotoxicity in tissue destruction was shown. 
 
II  The study of the long-term response to enzyme replacement treatment showed that 
gastrointestinal tract signs considered typical for dogs with EPI were kept almost completely 
in control with nonenteric-coated enzyme supplements in half of the dogs. The general health 
of these dogs was similar to that of clinically normal dogs of the same breeds. Despite 
basically similar treatment regimens, the responses varied considerably. Poor response to 
treatment was observed in 20% of the dogs with EPI. Although dietary sensitivities were 
common, the need for dietary treatment was minimal. Short relapses of clinical signs may 
develop during long-term treatment. To control these signs, antibiotics were administered to 
half of the dogs during treatment. Response to treatment achieved during the first months of 
treatment usually remained fairly stable during long-term treatment and the permanent 
deterioration of the clinical condition in dogs with EPI during long-term treatment is probably 
uncommon. Thus, in general, the prognosis for the long-term treatment of EPI with 
noneneteric-coated enzyme supplements is considered to be good. 
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